BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 454] [Cited by in F6Publishing: 386] [Article Influence: 34.9] [Reference Citation Analysis]
Number Citing Articles
1 Rich NE, Singal AG. Reply. Gastroenterology 2018;155:1275-6. [PMID: 30236560 DOI: 10.1053/j.gastro.2018.09.026] [Reference Citation Analysis]
2 Pelizzaro F, Peserico G, D'Elia M, Cazzagon N, Russo FP, Vitale A, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Trevisani F, Farinati F; Italian Liver Cancer (ITA.LI.CA) Study Group. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. Dig Liver Dis 2021:S1590-8658(21)00766-0. [PMID: 34580038 DOI: 10.1016/j.dld.2021.08.025] [Reference Citation Analysis]
3 Forner A. Hepatocellular carcinoma surveillance with miRNAs. Lancet Oncol 2015;16:743-5. [PMID: 26088271 DOI: 10.1016/S1470-2045(15)00014-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
4 Mueller PP, Chen Q, Ayer T, Nemutlu G, Hajjar A, Bethea ED, Peters MLB, Lee BP, Janjua NZ, Kanwal F, Chhatwal J. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.027] [Reference Citation Analysis]
5 An JY, Peña MA, Cunha GM, Booker MT, Taouli B, Yokoo T, Sirlin CB, Fowler KJ. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance. Radiographics 2020;40:1916-31. [PMID: 33136476 DOI: 10.1148/rg.2020200104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
6 Xia H, Huang Z, Liu S, Zhao X, He R, Wang Z, Shi W, Chen W, Li Z, Yu L, Huang P, Kang P, Su Z, Xu Y, Yam JWP, Cui Y. Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. Front Oncol 2021;11:653846. [PMID: 33869059 DOI: 10.3389/fonc.2021.653846] [Reference Citation Analysis]
7 Remington TL, Osman M, Simmonds K, Charlton C, Doucette K. Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B. CanLivJ 2020;3:263-75. [DOI: 10.3138/canlivj.2019-0024] [Reference Citation Analysis]
8 Maida M, Malizia G, Affronti A, Virdone R, Maida C, Margherita V, D’amico G. Screening and surveillance for hepatocellular carcinoma: perspective of a new era? Expert Review of Anticancer Therapy 2016;16:1291-302. [DOI: 10.1080/14737140.2016.1246965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Rodgers SK, Fetzer DT, Gabriel H, Seow JH, Choi HH, Maturen KE, Wasnik AP, Morgan TA, Dahiya N, O'Boyle MK, Kono Y, Sirlin CB, Kamaya A. Role of US LI-RADS in the LI-RADS Algorithm. Radiographics 2019;39:690-708. [PMID: 31059393 DOI: 10.1148/rg.2019180158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
10 Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167. [PMID: 31638892 DOI: 10.1186/s12876-019-1082-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E;  ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-iv255. [PMID: 30285213 DOI: 10.1093/annonc/mdy308] [Cited by in Crossref: 230] [Cited by in F6Publishing: 204] [Article Influence: 76.7] [Reference Citation Analysis]
12 Jiang HY, Chen J, Xia CC, Cao LK, Duan T, Song B. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol 2018; 24(22): 2348-2362 [PMID: 29904242 DOI: 10.3748/wjg.v24.i22.2348] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
13 Fetzer DT, Rodgers SK, Seow JH, Dawkins AA, Joshi G, Gabriel H, Kamaya A. Ultrasound Evaluation in Patients at Risk for Hepatocellular Carcinoma. Radiol Clin North Am. 2019;57:563-583. [PMID: 30928078 DOI: 10.1016/j.rcl.2019.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C. World J Hepatol 2015; 7(29): 2913-2919 [PMID: 26689503 DOI: 10.4254/wjh.v7.i29.2913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
15 Piñero F, Rubinstein F, Marciano S, Fernández N, Silva J, Zambelo Y, Anders M, Zerega A, Ridruejo E, Miguez C, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?Dig Dis Sci. 2019;64:718-728. [PMID: 30511199 DOI: 10.1007/s10620-018-5390-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Sengupta S, Parikh ND. Biomarker development for hepatocellular carcinoma early detection: Current and future perspectives. Hepat Oncol. 2017;4:111-122. [PMID: 30191058 DOI: 10.2217/hep-2017-0019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
17 Louka ML, Fawzy AM, Naiem AM, Elseknedy MF, Abdelhalim AE, Abdelghany MA. Vitamin D and K signaling pathways in hepatocellular carcinoma. Gene 2017;629:108-16. [PMID: 28764978 DOI: 10.1016/j.gene.2017.07.074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
18 Tan H, Martin P. Care of the Liver Transplant Candidate. Clinics in Liver Disease 2011;15:779-806. [DOI: 10.1016/j.cld.2011.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Shao C, Liu G, Zhang X, Li A, Guo X. Long Noncoding RNA RMRP Suppresses the Tumorigenesis of Hepatocellular Carcinoma Through Targeting microRNA-766. Onco Targets Ther 2020;13:3013-24. [PMID: 32308432 DOI: 10.2147/OTT.S243736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Farhang Zangneh H, Wong WWL, Sander B, Bell CM, Mumtaz K, Kowgier M, van der Meer AJ, Cleary SP, Janssen HLA, Chan KKW, Feld JJ. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. Clin Gastroenterol Hepatol. 2018;pii:S1542-3565(18)31394-6. [PMID: 30580095 DOI: 10.1016/j.cgh.2018.12.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
21 Alunni-Fabbroni M, Weber S, Öcal O, Seidensticker M, Mayerle J, Malfertheiner P, Ricke J. Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis. Cancers (Basel) 2021;13:521. [PMID: 33572923 DOI: 10.3390/cancers13030521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Singal AG. The efficacy and effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepat Oncol 2015;2:97-9. [PMID: 30190988 DOI: 10.2217/hep.14.38] [Reference Citation Analysis]
23 Giannini EG, Erroi V, Trevisani F. Effectiveness of α-fetoprotein for hepatocellular carcinoma surveillance: the return of the living-dead? Expert Rev Gastroenterol Hepatol 2012;6:441-4. [PMID: 22928896 DOI: 10.1586/egh.12.30] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Passos-Castilho AM, Carvalho VM, Cardozo KH, Kikuchi L, Chagas AL, Gomes-Gouvêa MS, Malta F, de Seixas-Santos Nastri AC, Pinho JR, Carrilho FJ, Granato CF. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry. BMC Cancer 2015;15:985. [PMID: 26680993 DOI: 10.1186/s12885-015-1995-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
25 Grgurevic I, Tjesic Drinkovic I, Pinzani M. Multiparametric ultrasound in liver diseases: an overview for the practising clinician. Postgrad Med J 2019;95:425-32. [PMID: 30665903 DOI: 10.1136/postgradmedj-2018-136111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
26 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer 2017;17:279. [PMID: 28420329 DOI: 10.1186/s12885-017-3267-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
27 Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clin Proc Innov Qual Outcomes 2019;3:302-10. [PMID: 31485568 DOI: 10.1016/j.mayocpiqo.2019.04.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
28 Kao JT, Feng CL, Yu CJ, Tsai SM, Hsu PN, Chen YL, Wu YY. IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study. BMC Gastroenterol 2015;15:50. [PMID: 25908103 DOI: 10.1186/s12876-015-0283-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
29 An J, Kim HI, Chang S, Shim JH. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma. PLoS One 2020;15:e0238078. [PMID: 32845895 DOI: 10.1371/journal.pone.0238078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Sutherland T, Watts J, Ryan M, Galvin A, Temple F, Vuong J, Little AF. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening. J Med Imaging Radiat Oncol. 2017;61:34-39. [PMID: 27558976 DOI: 10.1111/1754-9485.12513] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
31 Bird TG, Dimitropoulou P, Turner RM, Jenks SJ, Cusack P, Hey S, Blunsum A, Kelly S, Sturgeon C, Hayes PC. Alpha-Fetoprotein Detection of Hepatocellular Carcinoma Leads to a Standardized Analysis of Dynamic AFP to Improve Screening Based Detection. PLoS One. 2016;11:e0156801. [PMID: 27308823 DOI: 10.1371/journal.pone.0156801] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
32 Zheng SG, Xu HX, Liu LN. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol 2014; 6(1): 7-14 [PMID: 24578787 DOI: 10.4329/wjr.v6.i1.7] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
33 Demirtas CO, Gunduz F, Ozdogan OC. Surveillance Strategies for Hepatocellular Carcinoma: Recent Advances and the Shifting Paradigm. J Gastrointest Cancer 2021. [PMID: 34855124 DOI: 10.1007/s12029-021-00755-2] [Reference Citation Analysis]
34 Millet JD, Kamaya A, Choi HH, Dahiya N, Murphy PM, Naveed MZ, O’boyle M, Parra LA, Perez MG, Pirmoazen AM, Rodgers SK, Wasnik AP, Maturen KE. ACR Ultrasound Liver Reporting and Data System: Multicenter Assessment of Clinical Performance at One Year. Journal of the American College of Radiology 2019;16:1656-62. [DOI: 10.1016/j.jacr.2019.05.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
35 Plentz RR, Malek NP. Early Detection of Hepatocellular Carcinoma: How to Screen and Follow up Patients with Liver Cirrhosis According to the GERMAN S3 Guideline? Diagnostics (Basel) 2015;5:497-503. [PMID: 26854167 DOI: 10.3390/diagnostics5040497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
36 Bharadwaj S, Gohel TD. Perspectives of physicians regarding screening patients at risk of hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2016;4:237-40. [PMID: 25563577 DOI: 10.1093/gastro/gou089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
37 Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L, Perin T, Canzonieri V. Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications. Oncotarget. 2017;8:14192-14220. [PMID: 28077782 DOI: 10.18632/oncotarget.13929] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
38 Sato M, Morimoto K, Kajihara S, Tateishi R, Shiina S, Koike K, Yatomi Y. Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Sci Rep. 2019;9:7704. [PMID: 31147560 DOI: 10.1038/s41598-019-44022-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 8.7] [Reference Citation Analysis]
39 Kee K, Lu S. Diagnostic efficacy of ultrasound in hepatocellular carcinoma diagnosis. Expert Review of Gastroenterology & Hepatology 2017;11:277-9. [DOI: 10.1080/17474124.2017.1292126] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
40 Kang TW, Rhim H, Lee MW, Kim W, Park JG. Predicting Coverage of Transverse Subcostal Sonography With the Use of Previous Computed Tomography Before a Sonographic Liver Examination: A Prospective Study. Journal of Ultrasound in Medicine 2013;32:2053-61. [DOI: 10.7863/ultra.32.12.2053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Dhanasekaran R, Talwalkar JA. Quality of Cancer Care in Patients with Cirrhosis and Hepatocellular Carcinoma. Curr Gastroenterol Rep 2015;17:34. [PMID: 26238927 DOI: 10.1007/s11894-015-0459-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
42 Park HJ, Kim SY, Singal AG, Lee SJ, Won HJ, Byun JH, Choi SH, Yokoo T, Kim MJ, Lim YS. Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. Liver Int 2021. [PMID: 34817921 DOI: 10.1111/liv.15110] [Reference Citation Analysis]
43 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
44 Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843-853. [PMID: 25260312 DOI: 10.1016/j.bpg.2014.07.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
45 Ippolito D, Pecorelli A, Querques G, Drago SG, Maino C, Franzesi CT, Hatzidakis A, Sironi S. Dynamic Computed Tomography Perfusion Imaging: Complementary Diagnostic Tool in Hepatocellular Carcinoma Assessment From Diagnosis to Treatment Follow-up. Acad Radiol 2019;26:1675-85. [PMID: 30852079 DOI: 10.1016/j.acra.2019.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
46 Boal Carvalho P, Pereira E. Imagiological Diagnosis of Gastrointestinal Diseases - Diagnostic Criteria of Hepatocellular Carcinoma. GE Port J Gastroenterol 2015;22:153-60. [PMID: 28868398 DOI: 10.1016/j.jpge.2015.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
47 Méndez-Sánchez N, Ridruejo E, Alves de Mattos A, Chávez-Tapia NC, Zapata R, Paraná R, Mastai R, Strauss E, Guevara-Casallas LG, Daruich J, Gadano A, Parise ER, Uribe M, Aguilar-Olivos NE, Dagher L, Ferraz-Neto BH, Valdés-Sánchez M, Sánchez-Avila JF. Latin American Association for the Study of the Liver (LAASL) clinical practice guidelines: management of hepatocellular carcinoma. Ann Hepatol 2014;13 Suppl 1:S4-40. [PMID: 24998696 [PMID: 24998696 DOI: 10.1016/s1665-2681(19)30919-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
48 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol 2013; 5(6): 302-310 [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
49 Francica G. Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge. J Hepatocell Carcinoma 2017;4:23-7. [PMID: 28176952 DOI: 10.2147/JHC.S106558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
50 Caraiani C, Boca B, Bura V, Sparchez Z, Dong Y, Dietrich C. CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together? Biology (Basel) 2021;10:412. [PMID: 34066607 DOI: 10.3390/biology10050412] [Reference Citation Analysis]
51 Kim MN, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim DY. Longitudinal assessment of alpha-fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis. Scand J Gastroenterol 2019;54:1283-90. [PMID: 31593481 DOI: 10.1080/00365521.2019.1673478] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
52 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
53 Chandrapalan S, Bannaga A, Weidner A, Hitchins MP, Arasaradnam RP. A systematic review and meta-analysis: the diagnostic accuracy of methylated SEPTIN9 for the detection of hepatocellular carcinoma and the clinical evaluation of its use in combination with other surveillance modalities. Scand J Gastroenterol 2021;:1-8. [PMID: 34957898 DOI: 10.1080/00365521.2021.2020331] [Reference Citation Analysis]
54 An C, Kim DY, Choi JY, Han KH, Roh YH, Kim MJ. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial. BMC Cancer 2018;18:915. [PMID: 30249190 DOI: 10.1186/s12885-018-4827-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
55 Cai J, Chen L, Zhang Z, Zhang X, Lu X, Liu W, Shi G, Ge Y, Gao P, Yang Y, Ke A, Xiao L, Dong R, Zhu Y, Yang X, Wang J, Zhu T, Yang D, Huang X, Sui C, Qiu S, Shen F, Sun H, Zhou W, Zhou J, Nie J, Zeng C, Stroup EK, Chiu BC, Lau WY, He C, Wang H, Zhang W, Fan J. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68:2195-2205. [PMID: 31358576 DOI: 10.1136/gutjnl-2019-318882] [Cited by in Crossref: 59] [Cited by in F6Publishing: 64] [Article Influence: 19.7] [Reference Citation Analysis]
56 Ma XL, Zhu J, Wu J, Tian L, Gao YY, Zhang CY, Zhou Y, Dai Q, Wang BL, Pan BS, Zhou J, Fan J, Yang XR, Guo W. Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. Oncol Lett 2018;15:8396-404. [PMID: 29805574 DOI: 10.3892/ol.2018.8375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
57 Gomes MA, Priolli DG, Tralhão JG, Botelho MF. Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies. Rev Assoc Med Bras (1992) 2013;59:514-24. [PMID: 24041910 DOI: 10.1016/j.ramb.2013.03.005] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
58 Qu J, Yang J, Chen M, Cui L, Wang T, Gao W, Tian J, Wei R. MicroRNA-21 as a diagnostic marker for hepatocellular carcinoma: A systematic review and meta-analysis. Pak J Med Sci. 2019;35:1466-1471. [PMID: 31489028 DOI: 10.12669/pjms.35.5.685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
59 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
60 Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, Borzio F, Farinati F, Zoli M, Giannini EG, Caturelli E, Chiaramonte M, Trevisani F; Italian Liver Cancer (ITA.LI.CA) Group. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:1927-33.e2. [PMID: 24582947 DOI: 10.1016/j.cgh.2014.02.025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 69] [Article Influence: 8.0] [Reference Citation Analysis]
61 Lu M, Kong X, Wang H, Huang G, Ye C, He Z. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget 2017;8:8775-84. [PMID: 28060739 DOI: 10.18632/oncotarget.14452] [Cited by in Crossref: 40] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
62 Ricco G, Cosma C, Bedogni G, Biasiolo A, Guarino M, Pontisso P, Morisco F, Oliveri F, Cavallone D, Bonino F, Plebani M, Brunetto MR. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma. Cancer Biomark 2020;29:189-96. [PMID: 32623383 DOI: 10.3233/CBM-190118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
63 Kim BS. Noninvasive diagnosis of hepatocellular carcinoma. Clin Mol Hepatol 2012;18:245-7. [PMID: 22893878 DOI: 10.3350/cmh.2012.18.2.245] [Reference Citation Analysis]
64 Singal AG, Parikh ND, Rich NE, John BV, Pillai A. Hepatocellular Carcinoma Surveillance and Staging. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 27-51. [DOI: 10.1007/978-3-030-21540-8_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, Parikh ND, Browning T, Singal AG. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther 2017;45:169-77. [PMID: 27862091 DOI: 10.1111/apt.13841] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 19.5] [Reference Citation Analysis]
66 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
67 Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, Sparchez M, Stefanescu H, Mocan T. Ultrasound or Sectional Imaging Techniques as Screening Tools for Hepatocellular Carcinoma: Fall Forward or Move Forward? J Clin Med 2021;10:903. [PMID: 33668839 DOI: 10.3390/jcm10050903] [Reference Citation Analysis]
68 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29.epidemiology] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Sarkar M, Stewart S, Yu A, Chen MS, Nguyen TT, Khalili M. Hepatocellular carcinoma screening practices and impact on survival among hepatitis B-infected Asian Americans. J Viral Hepat 2012;19:594-600. [PMID: 22762144 DOI: 10.1111/j.1365-2893.2011.01577.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
70 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de-la-tijera F, Huitzil-meléndez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part I: Epidemiology and diagnosis. Revista de Gastroenterología de México (English Edition) 2022. [DOI: 10.1016/j.rgmxen.2021.10.009] [Reference Citation Analysis]
71 Gounder PP, Bulkow LR, Meltzer MI, Bruce MG, Hennessy TW, Snowball M, Spradling PR, Adhikari BB, McMahon BJ. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. Int J Circumpolar Health 2016;75:31115. [PMID: 27197711 DOI: 10.3402/ijch.v75.31115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
72 Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12 Suppl 2:S2. [PMID: 23173556 DOI: 10.1186/1471-2334-12-s2-s2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
73 Kisiel JB, Dukek BA, V S R Kanipakam R, Ghoz HM, Yab TC, Berger CK, Taylor WR, Foote PH, Giama NH, Onyirioha K, Abdallah MA, Burger KN, Slettedahl SW, Mahoney DW, Smyrk TC, Lewis JT, Giakoumopoulos M, Allawi HT, Lidgard GP, Roberts LR, Ahlquist DA. Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology. 2019;69:1180-1192. [PMID: 30168613 DOI: 10.1002/hep.30244] [Cited by in Crossref: 30] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
74 Josephus Jitta D, Wagenaar LJ, Mulder BJ, Guichelaar M, Bouman D, van Melle JP. Three cases of hepatocellular carcinoma in Fontan patients: Review of the literature and suggestions for hepatic screening. International Journal of Cardiology 2016;206:21-6. [DOI: 10.1016/j.ijcard.2015.12.033] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
75 Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Lee SS, Han K, Nam CM, Park SH, Lee KH. Contrast-enhanced US with Perfluorobutane for Hepatocellular Carcinoma Surveillance: A Multicenter Diagnostic Trial (SCAN). Radiology 2019;292:638-46. [PMID: 31287387 DOI: 10.1148/radiol.2019190183] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
76 Chen J, Zhu J, Zhang C, Song Y, Huang P. Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis. Eur Radiol 2020;30:2871-80. [PMID: 32020403 DOI: 10.1007/s00330-019-06649-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
78 Caviglia GP, Ciruolo M, Abate ML, Carucci P, Rolle E, Rosso C, Olivero A, Troshina G, Risso A, Nicolosi A, Ribaldone DG, Armandi A, Tandoi F, Saracco GM, Bugianesi E, Ciancio A, Gaia S. Alpha-Fetoprotein, Protein Induced by Vitamin K Absence or Antagonist II and Glypican-3 for the Detection and Prediction of Hepatocellular Carcinoma in Patients with Cirrhosis of Viral Etiology. Cancers (Basel) 2020;12:E3218. [PMID: 33142893 DOI: 10.3390/cancers12113218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Fujiwara N, Liu P, Athuluri-divakar SK, Zhu S, Hoshida Y. Risk Factors of Hepatocellular Carcinoma for Precision Personalized Care. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 3-25. [DOI: 10.1007/978-3-030-21540-8_1] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Cassinotto C, Aubé C, Dohan A. Diagnosis of hepatocellular carcinoma: An update on international guidelines. Diagn Interv Imaging 2017;98:379-91. [PMID: 28395852 DOI: 10.1016/j.diii.2017.01.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
81 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis. 2013;17:375-397. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
82 Kim SS, Baek GO, Ahn HR, Sung S, Seo CW, Cho HJ, Nam SW, Cheong JY, Eun JW. Serum small extracellular vesicle-derived LINC00853 as a novel diagnostic marker for early hepatocellular carcinoma. Mol Oncol. 2020;14:2646-2659. [PMID: 32525601 DOI: 10.1002/1878-0261.12745] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
83 Qian Y, Wang JW, Fang Y, Yuan XD, Fan YC, Gao S, Wang K. Measurement of Cyclin D2 (CCND2) Gene Promoter Methylation in Plasma and Peripheral Blood Mononuclear Cells and Alpha-Fetoprotein Levels in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma. Med Sci Monit 2020;26:e927444. [PMID: 33320844 DOI: 10.12659/MSM.927444] [Reference Citation Analysis]
84 Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl 2018;24:1171-7. [PMID: 29781162 DOI: 10.1002/lt.25202] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
85 Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, Kelly D, Mieli-vergani G. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines. Journal of Hepatology 2013;59:814-29. [DOI: 10.1016/j.jhep.2013.05.016] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 13.4] [Reference Citation Analysis]
86 Cross TJS, Villanueva A, Shetty S, Wilkes E, Collins P, Adair A, Jones RL, Foxton MR, Meyer T, Stern N, Warshow U, Khan N, Prince M, Khakoo S, Alexander GJ, Khan S, Reeves H, Marshall A, Williams R. A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma. Frontline Gastroenterol 2016;7:82-9. [PMID: 28840911 DOI: 10.1136/flgastro-2015-100617] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
87 Orloff MJ, Isenberg JI, Wheeler HO, Haynes KS, Jinich-Brook H, Rapier R, Vaida F, Hye RJ, Orloff SL. A randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis for hepatocellular carcinoma. Am J Surg 2012;203:182-90. [PMID: 21679921 DOI: 10.1016/j.amjsurg.2011.02.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
88 Ahmed NNA, El Gaafary SM, Elia RZ, Abdulhafiz EM. Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment. Egypt J Radiol Nucl Med 2020;51. [DOI: 10.1186/s43055-020-00199-x] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
89 De Sanctis V, Soliman AT, Daar S, Alansary N, Kattamis A, Skafida M, Galati MC, Christou S, Campisi S, Messina G, Yassin MA, Canatan D, Di Maio S, Al Jaouni S, Raiola G, Karimi M, Kaleva V, Kakkar S, Mariannis D, Kattamis C. A Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (HCC) in β-Thalassemias: Past, Present and Future Perspectives and the ICET-A Experience. Mediterr J Hematol Infect Dis 2020;12:e2020006. [PMID: 31934316 DOI: 10.4084/MJHID.2020.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
90 Park HJ, Jang HY, Kim SY. Reply to: "Non-enhanced magnetic resonance as a surveillance tool for hepatocellular carcinoma: Many unresolved issues". J Hepatol 2020;73:213-4. [PMID: 32223917 DOI: 10.1016/j.jhep.2020.03.004] [Reference Citation Analysis]
91 Liu CH, Gil-Gómez A, Ampuero J, Romero-Gómez M. Diagnostic accuracy of SCCA and SCCA-IgM for hepatocellular carcinoma: A meta-analysis. Liver Int 2018;38:1820-31. [PMID: 29704434 DOI: 10.1111/liv.13867] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
92 Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
93 Cheung CY, Lam MF, Chow KM, Lee W, Cheng YL, Yuen SK, Wong PN, Mo KL, Leung KT, Wong SH, Ho YW, Chau KF. Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong Renal Registry. Renal Failure 2014;36:865-9. [DOI: 10.3109/0886022x.2014.899879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S34-43. [PMID: 21739567 DOI: 10.1002/lt.22369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
95 Zech CJ, Bartolozzi C, Bioulac-sage P, Chow PK, Forner A, Grazioli L, Huppertz A, Laumonier H, Min Lee J, Murakami T, Ricke J, Sirlin CB. Consensus Report of the Fifth International Forum for Liver MRI. American Journal of Roentgenology 2013;201:97-107. [DOI: 10.2214/ajr.12.9491] [Cited by in Crossref: 32] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
96 Uyei J, Taddei TH, Kaplan DE, Chapko M, Stevens ER, Braithwaite RS. Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study. PLoS One 2019;14:e0221614. [PMID: 31449554 DOI: 10.1371/journal.pone.0221614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
97 Choi HH, Rodgers SK, Fetzer DT, Wasnik AP, Millet JD, Morgan TA, Dawkins A, Gabriel H, Kamaya A. Ultrasound Liver Imaging Reporting and Data System (US LI-RADS): An Overview with Technical and Practical Applications. Acad Radiol 2020:S1076-6332(20)30354-8. [PMID: 32718745 DOI: 10.1016/j.acra.2020.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
98 Zhang XP, Wang K, Cheng SQ. Surveillance for Early-Stage Hepatocellular Carcinoma by Ultrasound Plus Alpha-Fetoprotein Measurement: More Details, More Significance. Gastroenterology 2018;155:1274-5. [PMID: 30227109 DOI: 10.1053/j.gastro.2018.03.071] [Reference Citation Analysis]
99 Choi HH, Perez MG, Millet JD, Liang T, Wasnik AP, Maturen KE, Kamaya A. Association of advanced hepatic fibrosis and sonographic visualization score: a dual-center study using ACR US LI-RADS. Abdom Radiol 2019;44:1415-22. [DOI: 10.1007/s00261-018-1862-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
100 Pelizzaro F, Vitale A, Sartori A, Vieno A, Penzo B, Russo FP, Frigo AC, Giannini EG, Piccinnu M, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Celsa C, Marra F, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Olivani A, Masotto A, Coccoli P, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F, On Behalf Of Ita Li Ca Study Group. Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients. Cancers (Basel) 2021;13:897. [PMID: 33672751 DOI: 10.3390/cancers13040897] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
101 Schwarze V, Rübenthaler J, Marschner C, Fabritius MP, Rueckel J, Fink N, Puhr-Westerheide D, Gresser E, Froelich MF, Schnitzer ML, Große Hokamp N, Afat S, Staehler M, Geyer T, Clevert DA. Advanced Fusion Imaging and Contrast-Enhanced Imaging (CT/MRI-CEUS) in Oncology. Cancers (Basel) 2020;12:E2821. [PMID: 33007933 DOI: 10.3390/cancers12102821] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
102 Suh YJ, Jin YJ, Jeong Y, Shin WY, Lee JM, Cho S, Yu JH, Lee JW. Resection or ablation versus transarterial therapy for Child-Pugh A patients with a single small hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e27470. [PMID: 34713824 DOI: 10.1097/MD.0000000000027470] [Reference Citation Analysis]
103 Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol 2015; 7(12): 1632-1651 [PMID: 26140083 DOI: 10.4254/wjh.v7.i12.1632] [Cited by in Crossref: 120] [Cited by in F6Publishing: 107] [Article Influence: 17.1] [Reference Citation Analysis]
104 Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, Nehra M, Lee WM, Marrero JA, Tiro JA. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124-30. [PMID: 22846843 DOI: 10.1158/1940-6207.CAPR-12-0046] [Cited by in Crossref: 120] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]
105 Sharma P, Saini SD, Kuhn LB, Rubenstein JH, Pardi DS, Marrero JA, Schoenfeld PS. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci. 2011;56:569-577. [PMID: 20978844 DOI: 10.1007/s10620-010-1453-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
106 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199.] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
107 Díaz-González Á, Forner A. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2016;30:1001-10. [PMID: 27938779 DOI: 10.1016/j.bpg.2016.10.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
108 Rethy A, Langø T, Mårvik R. Laparoscopic Ultrasound for Hepatocellular Carcinoma and Colorectal Liver Metastasis: An Overview. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques 2013;23:135-44. [DOI: 10.1097/sle.0b013e31828a0b9a] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
109 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
110 Milgrom DP, Maluccio MA, Koniaris LG. Management of Hepatocellular Carcinoma (HCC). Curr Surg Rep 2016;4. [DOI: 10.1007/s40137-016-0143-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
111 Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma: . Current Opinion in Gastroenterology 2010;26:189-95. [DOI: 10.1097/mog.0b013e3283383ca5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
112 Soresi M, Terranova A, Licata A, Serruto A, Montalto G, Brancatelli G, Giannitrapani L. Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. Biomed Res Int 2017;2017:4932759. [PMID: 28638828 DOI: 10.1155/2017/4932759] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
113 Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, Benvegnù L, Farinati F, Zoli M. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53:291-297. [PMID: 20483497 DOI: 10.1016/j.jhep.2010.03.010] [Cited by in Crossref: 184] [Cited by in F6Publishing: 171] [Article Influence: 15.3] [Reference Citation Analysis]
114 Pelizzaro F, Cardin R, Penzo B, Pinto E, Vitale A, Cillo U, Russo FP, Farinati F. Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now? Cancers (Basel) 2021;13:2274. [PMID: 34068786 DOI: 10.3390/cancers13092274] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Dulku G, Dhillon R, Goodwin M, Cheng W, Kontorinis N, Mendelson R. The role of imaging in the surveillance and diagnosis of hepatocellular cancer. J Med Imaging Radiat Oncol 2017;61:171-9. [DOI: 10.1111/1754-9485.12568] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
116 Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323-324, vii-x. [PMID: 21689616 DOI: 10.1016/j.cld.2011.03.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
117 Zaki IH, Shropshire E, Zhang S, Xiao D, Wildman-Tobriner B, Marin D, Gupta RT, Erkanli A, Nelson RC, Bashir MR. How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine? Abdom Radiol (NY) 2021;46:969-78. [PMID: 32951065 DOI: 10.1007/s00261-020-02771-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
118 Hemming AW, Berumen J, Mekeel K. Hepatitis B and Hepatocellular Carcinoma. Clin Liver Dis. 2016;20:703-720. [PMID: 27742009 DOI: 10.1016/j.cld.2016.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
119 Padhya KT, Marrero JA, Singal AG. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2013;29:285-292. [PMID: 23507917 DOI: 10.1097/mog.0b013e32835ff1cf] [Cited by in Crossref: 70] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
120 Villacastín Ruiz E, Caro-Patón Gómez A, Calero Aguilar H, Pérez Saborido B, García Pajares F, Sánchez Antolín G, Madrigal Rubiales B, Pacheco Sánchez D, Pintado Garrido R, Plaza Loma S, Escudero Caro T. Review of imaging techniques in the diagnosis of hepatocellular carcinoma in patients who require a liver transplant. Eur J Gastroenterol Hepatol 2016;28:412-20. [PMID: 26760587 DOI: 10.1097/MEG.0000000000000528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
121 Zheng J, Zhu MY, Wu F, Kang B, Liang J, Heskia F, Shan YF, Zhang XX. A blood-based 22-gene expression signature for hepatocellular carcinoma identification. Ann Transl Med 2020;8:195. [PMID: 32309342 DOI: 10.21037/atm.2020.01.93] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987-1997. [PMID: 22144108 DOI: 10.1002/hep.24545] [Cited by in Crossref: 212] [Cited by in F6Publishing: 195] [Article Influence: 21.2] [Reference Citation Analysis]
123 Joshi K, Mendler M, Gish R, Loomba R, Kuo A, Patton H, Kono Y. Hepatocellular carcinoma surveillance: a national survey of current practices in the USA. Dig Dis Sci 2014;59:3073-7. [PMID: 25027206 DOI: 10.1007/s10620-014-3256-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
124 Chen S, Xu XL, Zhou B, Tian J, Luo BM, Zhang LM. Acidic pH-Activated Gas-Generating Nanoparticles with Pullulan Decorating for Hepatoma-Targeted Ultrasound Imaging. ACS Appl Mater Interfaces 2019;11:22194-205. [PMID: 31199110 DOI: 10.1021/acsami.9b06745] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
125 Tillman BG, Gorman JD, Hru JM, Lee MH, King MC, Sirlin CB, Marks RM. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol 2018;73:485-93. [PMID: 29246586 DOI: 10.1016/j.crad.2017.11.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
126 Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, Singal AG. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014;12:870-7. [PMID: 24095974 DOI: 10.1016/j.cgh.2013.09.053] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
127 Lee HJ, Yeon JE, Suh SJ, Lee SJ, Yoon EL, Kang K, Yoo YJ, Kim JH, Seo YS, Yim HJ. Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver. 2014;8:177-185. [PMID: 24672660 DOI: 10.5009/gnl.2014.8.2.177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
128 Schwarze V, Marschner C, Völckers W, Grosu S, Negrão de Figueiredo G, Rübenthaler J, Clevert DA. Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients. J Int Med Res 2020;48:300060520930151. [PMID: 32529869 DOI: 10.1177/0300060520930151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
129 Khatri G, Pedrosa I, Ananthakrishnan L, Leon AD, Fetzer DT, Leyendecker J, Singal AG, Xi Y, Yopp A, Yokoo T. Abbreviated‐protocol screening MRI vs. complete‐protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI‐RADS v2018. J Magn Reson Imaging 2019;51:415-25. [DOI: 10.1002/jmri.26835] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
130 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019; 7(16): 2269-2286 [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
131 Stefanini B, Tonnini M, Serio I, Renzulli M, Tovoli F. Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement. Expert Rev Anticancer Ther 2022;:1-11. [PMID: 35263211 DOI: 10.1080/14737140.2022.2052276] [Reference Citation Analysis]
132 Jeong WK. Surveillance of hepatocellular carcinoma: is only ultrasound enough? Clin Mol Hepatol 2017;23:222-3. [PMID: 28942623 DOI: 10.3350/cmh.2017.0046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
133 Singal AG, Tiro JA, Marrero JA, McCallister K, Mejias C, Adamson B, Bishop WP, Santini NO, Halm EA. Mailed Outreach Program Increases Ultrasound Screening of Patients With Cirrhosis for Hepatocellular Carcinoma. Gastroenterology. 2017;152:608-615.e4. [PMID: 27825963 DOI: 10.1053/j.gastro.2016.10.042] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 8.0] [Reference Citation Analysis]
134 Ng J, Necas M, Toit T. The visualisation of focal liver lesions on ultrasound: A review of 300 liver ultrasounds with CT or MRI correlation. Sonography 2020;7:7-12. [DOI: 10.1002/sono.12206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
135 Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol. 2013;11:472-477. [PMID: 23200983 DOI: 10.1016/j.cgh.2012.11.010] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
136 Czaja AJ. Review article: the management of autoimmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther 2013;38:343-64. [DOI: 10.1111/apt.12381] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
137 Vivarelli M, Montalti R, Risaliti A. Multimodal treatment of hepatocellular carcinoma on cirrhosis: an update. World J Gastroenterol 2013;19:7316-26. [PMID: 24259963 DOI: 10.3748/wjg.v19.i42.7316] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
138 Erstad DJ, Tanabe KK. Hepatocellular carcinoma: early-stage management challenges. J Hepatocell Carcinoma 2017;4:81-92. [PMID: 28721349 DOI: 10.2147/JHC.S107370] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
139 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
140 Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, Singal AG. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology 2018; 154: 1706-1718. e1. [PMID: 29425931 DOI: 10.1053/j.gastro.2018.01.064] [Cited by in Crossref: 242] [Cited by in F6Publishing: 236] [Article Influence: 60.5] [Reference Citation Analysis]
141 Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? World J Exp Med 2016; 6(1): 21-36 [PMID: 26929917 DOI: 10.5493/wjem.v6.i1.21] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 12.5] [Reference Citation Analysis]
142 Duffy MJ. Use of Biomarkers in Screening for Cancer. Adv Exp Med Biol 2015;867:27-39. [PMID: 26530358 DOI: 10.1007/978-94-017-7215-0_3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
143 Benner K, Flora K, Newell P. Developing a liver cancer program in the nonacademic medical center. Clin Liver Dis (Hoboken) 2017;9:25-8. [PMID: 30992952 DOI: 10.1002/cld.616] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
144 Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero JA, Yopp AC, Parikh ND, Scaglione SJ. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. Am J Med. 2017;130:1099-1106.e1. [PMID: 28213044 DOI: 10.1016/j.amjmed.2017.01.021] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
145 Adeniji N, Dhanasekaran R. Current and Emerging Tools for Hepatocellular Carcinoma Surveillance. Hepatol Commun 2021. [PMID: 34533885 DOI: 10.1002/hep4.1823] [Reference Citation Analysis]
146 DiStefano JK. Long noncoding RNAs in the initiation, progression, and metastasis of hepatocellular carcinoma. Noncoding RNA Res 2017;2:129-36. [PMID: 30159431 DOI: 10.1016/j.ncrna.2017.11.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
147 Chung YE, Kim MJ, Park MS, Choi JY, Lim JS, Kim KA, Kim KW. The impact of CT follow-up interval on stages of hepatocellular carcinomas detected during the surveillance of patients with liver cirrhosis. AJR Am J Roentgenol 2012;199:816-21. [PMID: 22997373 DOI: 10.2214/AJR.11.8100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
148 Chen Q, Ayer T, Chhatwal J. Optimal M -Switch Surveillance Policies for Liver Cancer in a Hepatitis C–Infected Population. Operations Research 2018;66:673-96. [DOI: 10.1287/opre.2017.1706] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
149 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624. [PMID: 24691105 DOI: 10.1371/journal.pmed.1001624] [Cited by in Crossref: 364] [Cited by in F6Publishing: 339] [Article Influence: 45.5] [Reference Citation Analysis]
150 Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Amarapurkar D. Screening for hepatocellular carcinoma: Good enough but best yet to come: Editorials. Journal of Gastroenterology and Hepatology 2010;25:845-6. [DOI: 10.1111/j.1440-1746.2010.06276.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
152 Yang Y, Li G, Lu Z, Liu Y, Kong J, Liu J. Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma. Front Oncol 2021;11:726213. [PMID: 34900676 DOI: 10.3389/fonc.2021.726213] [Reference Citation Analysis]
153 Tayyab GUN, Rasool S, Nasir B, Rubi G, Abou-Samra AB, Butt AA. Hepatocellular carcinoma occurs frequently and early after treatment in HCV genotype 3 infected persons treated with DAA regimens. BMC Gastroenterol 2020;20:93. [PMID: 32252635 DOI: 10.1186/s12876-020-01249-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
154 Bashir MR, Hussain HK. Imaging in Patients with Cirrhosis. Radiologic Clinics of North America 2015;53:919-31. [DOI: 10.1016/j.rcl.2015.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
155 Núñez Martínez Ó, Matilla Peña A, Merino Rodríguez B, Díaz Sánchez A, Colón Rodríguez A, Ramón Botella E, Yepes Barreto I, Prieto Martín M, Tellado Rodríguez JM, Clemente Ricote G. Estudio descriptivo de la experiencia sobre carcinoma hepatocelular en hígado no cirrótico. Gastroenterología y Hepatología 2011;34:322-8. [DOI: 10.1016/j.gastrohep.2011.02.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
156 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S391-405. [DOI: 10.1016/j.jacr.2017.08.045] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
157 Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:791-8.e1. [PMID: 25019694 DOI: 10.1016/j.cgh.2014.06.031] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 7.5] [Reference Citation Analysis]
158 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
159 Lim TS, Kim DY, Han KH, Kim HS, Shin SH, Jung KS, Kim BK, Kim SU, Park JY, Ahn SH. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol. 2016;51:344-353. [PMID: 26340708 DOI: 10.3109/00365521.2015.1082190] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 5.7] [Reference Citation Analysis]
160 Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16:804-815. [PMID: 26088272 DOI: 10.1016/s1470-2045(15)00048-0] [Cited by in Crossref: 158] [Cited by in F6Publishing: 107] [Article Influence: 22.6] [Reference Citation Analysis]
161 Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, Taouli B, Chung RT, Hoshida Y. Cost-Effectiveness of Risk Score-Stratified Hepatocellular Carcinoma Screening in Patients with Cirrhosis. Clin Transl Gastroenterol 2017;8:e101. [PMID: 28640287 DOI: 10.1038/ctg.2017.26] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 12.8] [Reference Citation Analysis]
162 Kheraj R, Tewani SK, Ketwaroo G, Leffler DA. Quality improvement in gastroenterology clinical practice. Clin Gastroenterol Hepatol. 2012;10:1305-1314. [PMID: 22902758 DOI: 10.1016/j.cgh.2012.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
163 Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Review of Gastroenterology & Hepatology 2015;9:603-27. [DOI: 10.1586/17474124.2015.1007955] [Cited by in Crossref: 70] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
164 Reiter FP, Hadjamu NJ, Nagdyman N, Zachoval R, Mayerle J, De Toni EN, Kaemmerer H, Denk G. Congenital heart disease-associated liver disease: a narrative review. Cardiovasc Diagn Ther 2021;11:577-90. [PMID: 33968635 DOI: 10.21037/cdt-20-595] [Reference Citation Analysis]
165 Singal AG, Li X, Tiro J, Kandunoori P, Adams-Huet B, Nehra MS, Yopp A. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2015;128:90.e1-90.e7. [PMID: 25116425 DOI: 10.1016/j.amjmed.2014.07.027] [Cited by in Crossref: 74] [Cited by in F6Publishing: 77] [Article Influence: 9.3] [Reference Citation Analysis]
166 Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-95. [PMID: 26607931 DOI: 10.1007/s12094-015-1451-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
167 Waghray A, Murali AR, Menon KN. Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol 2015; 7(8): 1020-1029 [PMID: 26052391 DOI: 10.4254/wjh.v7.i8.1020] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 11.6] [Reference Citation Analysis]
168 Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: A systematic review. J Gen Intern Med. 2012;27:861-867. [PMID: 22215266 DOI: 10.1007/s11606-011-1952-x] [Cited by in Crossref: 166] [Cited by in F6Publishing: 154] [Article Influence: 16.6] [Reference Citation Analysis]
169 Kim DY, Kim HJ, Jeong SE, Kim SG, Kim HJ, Sinn DH, Lee YJ, Jeong WK, Choi KS, Heo N, Kim DJ, Kim YS, Kim YB, Kim YJ, Kim H, Park M, Lee CW, Tak WY, Chung JH, Kim SY, Kim Y, Lee W, Kim HS. The Korean guideline for hepatocellular carcinoma surveillance. J Korean Med Assoc 2015;58:385. [DOI: 10.5124/jkma.2015.58.5.385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
170 Reitz S, Slam K, Chambers LW. Biliary, pancreatic, and hepatic imaging for the general surgeon. Surg Clin North Am. 2011;91:59-92. [PMID: 21184901 DOI: 10.1016/j.suc.2010.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Liao Q, Han P, Huang Y, Wu Z, Chen Q, Li S, Ye J, Wu X. Potential Role of Circulating microRNA-21 for Hepatocellular Carcinoma Diagnosis: A Meta-Analysis. PLoS One. 2015;10:e0130677. [PMID: 26114756 DOI: 10.1371/journal.pone.0130677] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
172 Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, Kim HJ, Kim KW, Lee SS. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol 2020;30:2302-11. [DOI: 10.1007/s00330-019-06546-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
173 Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an italian in-field experience. Dig Dis Sci. 2015;60:1465-1473. [PMID: 25399329 DOI: 10.1007/s10620-014-3427-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
174 Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Parikh N, Browning T, Singal AG. Editorial: ultrasound surveillance of hepatocellular carcinoma in the 21st century - authors' reply. Aliment Pharmacol Ther 2017;45:562-3. [PMID: 28074510 DOI: 10.1111/apt.13910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Chon YE, Jung KS, Kim MJ, Choi JY, An C, Park JY, Ahn SH, Kim BK, Kim SU, Park H, Hwang SK, Rim KS, Han KH, Kim DY. Predictors of failure to detect early hepatocellular carcinoma in patients with chronic hepatitis B who received regular surveillance. Aliment Pharmacol Ther 2018;47:1201-12. [PMID: 29492988 DOI: 10.1111/apt.14578] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
176 Gaba RC, Kallwitz ER, Parvinian A, Bui JT, Roenn NMV, Berkes JL, Cotler SJ. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients. Annals of Hepatology 2013;12:766-73. [DOI: 10.1016/s1665-2681(19)31318-3] [Cited by in Crossref: 21] [Article Influence: 2.3] [Reference Citation Analysis]
177 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
178 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
179 Paranaguá-Vezozzo DC, Ono SK, Alvarado-Mora MV, Farias AQ, Cunha-Silva M, França JI, Alves VA, Sherman M, Carrilho FJ. Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort. Ann Hepatol 2014;13:386-93. [PMID: 24927609 [PMID: 24927609 DOI: 10.1016/s1665-2681(19)30845-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
180 Chaiteerakij R, Chattieng P, Choi J, Pinchareon N, Thanapirom K, Geratikornsupuk N. Surveillance for Hepatocellular Carcinoma Reduces Mortality: an Inverse Probability of Treatment Weighted Analysis. Annals of Hepatology 2017;16:421-9. [DOI: 10.5604/01.3001.0009.8597] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
181 Abou-alfa GK, Wu L, Villanueva A. Novel Non-Protein Biomarkers for Early Detection of Hepatocellular Carcinoma. Engineering 2021;7:1369-74. [DOI: 10.1016/j.eng.2021.02.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Schreiber-Dietrich D, Pohl M, Cui XW, Braden B, Dietrich CF, Chiorean L. Perihepatic lymphadenopathy in children with chronic viral hepatitis. J Ultrason. 2015;15:137-150. [PMID: 26676184 DOI: 10.15557/jou.2015.0012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
183 Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Imaging 2019;10:8. [PMID: 30694398 DOI: 10.1186/s13244-019-0690-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
184 Ko HH, Wong DK, Heathcote J. Management of hepatitis B. Clin Gastroenterol Hepatol 2011;9:385-91. [PMID: 21185398 DOI: 10.1016/j.cgh.2010.12.015] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
185 Battaglia V, Cervelli R. Liver investigations: Updating on US technique and contrast-enhanced ultrasound (CEUS). Eur J Radiol. 2017;96:65-73. [PMID: 29103478 DOI: 10.1016/j.ejrad.2017.08.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
186 Parikh ND. PRO: Hepatocellular Carcinoma Surveillance: A Useful Tool Against the Rising Tide of HCC. Am J Gastroenterol 2017;112:1632-3. [PMID: 28972597 DOI: 10.1038/ajg.2017.366] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
187 Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world? Clin Mol Hepatol 2017;23:239-48. [PMID: 28706177 DOI: 10.3350/cmh.2017.0008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
188 Webb GJ, Wright KV, Harrod EC, Gorard DA, Collier JD, Evans AK. Surveillance for hepatocellular carcinoma in a mixed-aetiology UK cohort with cirrhosis: does α-fetoprotein still have a role? Clin Med (Lond) 2015;15:139-44. [PMID: 25824065 DOI: 10.7861/clinmedicine.15-2-139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
189 Richardson P, Henderson L, Davila JA, Kramer JR, Fitton CP, Chen GJ, El-Serag HB. Surveillance for hepatocellular carcinoma: development and validation of an algorithm to classify tests in administrative and laboratory data. Dig Dis Sci 2010;55:3241-51. [PMID: 20844957 DOI: 10.1007/s10620-010-1387-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
190 Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program. Liver Transpl 2019;25:369-79. [PMID: 30582779 DOI: 10.1002/lt.25398] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
191 Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [PMID: 28620797 DOI: 10.1007/s12072-017-9799-9] [Cited by in Crossref: 661] [Cited by in F6Publishing: 667] [Article Influence: 132.2] [Reference Citation Analysis]
192 Carrillo FJ, Mattos AA, Vianey AF, Vezozzo DC, Marinho F, Souto FJ, Cotrim HP, Coelho HS, Silva I, Garcia JH. Brazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinoma. Arq Gastroenterol. 2015;52 Suppl 1:2-14. [PMID: 26959803 DOI: 10.1590/s0004-28032015000500001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
193 Ronot M, Pommier R, Dioguardi Burgio M, Purcell Y, Nahon P, Vilgrain V. Hepatocellular carcinoma surveillance with ultrasound-cost-effectiveness, high-risk populations, uptake. Br J Radiol 2018;91:20170436. [PMID: 29446324 DOI: 10.1259/bjr.20170436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
194 Dietrich CF, Teufel A, Sirlin CB, Dong Y. Surveillance of hepatocellular carcinoma by medical imaging. Quant Imaging Med Surg 2019;9:1904-10. [PMID: 31867241 DOI: 10.21037/qims.2019.10.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
195 Kim YY, An C, Kim DY, Aljoqiman KS, Choi JY, Kim MJ. Failure of hepatocellular carcinoma surveillance: inadequate echogenic window and macronodular parenchyma as potential culprits. Ultrasonography 2019;38:311-20. [PMID: 31079440 DOI: 10.14366/usg.18051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
196 Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection: Highly sensitive HCC biomarkers. Hepatol Res 2016;46:E130-5. [DOI: 10.1111/hepr.12544] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
197 Minami T, Tateishi R, Kondo M, Nakagomi R, Fujiwara N, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Moriya K, Shiina S, Koike K. Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine (Baltimore) 2015;94:e901. [PMID: 26061310 DOI: 10.1097/MD.0000000000000901] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
198 Goossens N, Bian CB, Hoshida Y. Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep 2017;16:64-71. [PMID: 28337405 DOI: 10.1007/s11901-017-0336-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
199 Zheng H, Li P, Kwok JG, Korrapati A, Li WT, Qu Y, Wang XQ, Kisseleva T, Wang-Rodriguez J, Ongkeko WM. Alcohol and hepatitis virus-dysregulated lncRNAs as potential biomarkers for hepatocellular carcinoma. Oncotarget 2018;9:224-35. [PMID: 29416609 DOI: 10.18632/oncotarget.22921] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
200 Hao PP, Liu YP, Yang CY, Liang T, Zhang C, Song J, Han JK, Hou GH. Evaluation of (131)I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma. PLoS One 2014;9:e85002. [PMID: 24416333 DOI: 10.1371/journal.pone.0085002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
201 Cucchetti A, Trevisani F, Cescon M, Ercolani G, Farinati F, Poggio PD, Rapaccini G, Nolfo MAD, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Pinna AD. Cost-effectiveness of semi-annual surveillance for hepatocellular carcinoma in cirrhotic patients of the Italian Liver Cancer population. Journal of Hepatology 2012;56:1089-96. [DOI: 10.1016/j.jhep.2011.11.022] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 4.2] [Reference Citation Analysis]
202 Surveillance group. ; Diagnosis group; Staging group; Surgery group; Local ablation group; TACE/TARE/HAI group; Target therapy/systemic therapy group; Radiotherapy group; Prevention group; Drafting group. Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. J Formos Med Assoc. 2018;117:381-403. [PMID: 29074347 DOI: 10.1016/j.jfma.2017.09.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 9.4] [Reference Citation Analysis]
203 Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. Clin Gastroenterol Hepatol. 2016;14:875-886.e6. [PMID: 26775025 DOI: 10.1016/j.cgh.2015.12.042] [Cited by in Crossref: 102] [Cited by in F6Publishing: 99] [Article Influence: 17.0] [Reference Citation Analysis]
204 Zhang Y, Zhao J, Cai J, Ye JC, Xiao YT, Mei Y, Zeng MS, Xie CM, Jiang Y, Feng GK. Integrin α6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice. Mol Imaging Biol 2020;22:864-72. [PMID: 31792839 DOI: 10.1007/s11307-019-01437-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Yamaoka K, Saitoh S, Kinowaki K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Fukusato T, Kumada H. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2021;:101799. [PMID: 34500120 DOI: 10.1016/j.clinre.2021.101799] [Reference Citation Analysis]
206 Sherman M. Limitations of screening for hepatocellular carcinoma. Hepat Oncol 2014;1:161-3. [PMID: 30190948 DOI: 10.2217/hep.13.22] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
207 Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time. Clin Gastroenterol Hepatol. 2013;11:437-440. [PMID: 23247324 DOI: 10.1016/j.cgh.2012.11.029] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
208 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
209 Malov SI, Malov IV, Kuvshinov AG, Marche PN, Decaens T, Macek-Jilkova Z, Yushchuk ND. Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C. Sovrem Tekhnologii Med 2021;13:27-33. [PMID: 34513063 DOI: 10.17691/stm2021.13.1.03] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Zhu L, Li T, Ma X, Qiu Y, Ma X, Lin Y, Han L, Qin C. A Simple Noninvasive Index Can Predict Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Sci Rep 2017;7:8954. [PMID: 28827721 DOI: 10.1038/s41598-017-09358-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
211 Madaleno J, Alves R, Silva N, Calretas S, Tomé L, Ferrão J, Barros A, Diogo D, Cipriano A, Furtado E, Carvalho A. Incidentally Discovered Hepatocellular Carcinoma in Explanted Liver: Clinical, Histopathologic Features and Outcome. Transplantation Proceedings 2015;47:1051-4. [DOI: 10.1016/j.transproceed.2015.04.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
212 Karabulut S, Tas F, Akyüz F, Ormeci AC, Serilmez M, Soydinç HO, Vatansever S, Yasasever V. Clinical significance of serum hepatocyte growth factor (HGF) levels in hepatocellular carcinoma. Tumour Biol 2014;35:2327-33. [PMID: 24142532 DOI: 10.1007/s13277-013-1308-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
213 Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, Murphy C, McCallister K, Singal AG. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2017;65:1196-1205. [PMID: 27775821 DOI: 10.1002/hep.28895] [Cited by in Crossref: 97] [Cited by in F6Publishing: 96] [Article Influence: 16.2] [Reference Citation Analysis]
214 Charrière B, Maulat C, Suc B, Muscari F. Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma. World J Hepatol 2016; 8(21): 881-890 [PMID: 27478538 DOI: 10.4254/wjh.v8.i21.881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
215 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015; 7(3): 362-376 [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 10.6] [Reference Citation Analysis]
216 Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol 2021;75:108-19. [PMID: 33548385 DOI: 10.1016/j.jhep.2021.01.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
217 Weiskirchen R, Tacke F. The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Curr Hepatology Rep 2018;17:324-35. [DOI: 10.1007/s11901-018-0421-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
218 Chavda HJ. Hepatocellular Carcinoma in India. Indian J Surg 2021;83:959-66. [DOI: 10.1007/s12262-021-02762-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Lozada ME, Chaiteerakij R, Roberts LR. Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? Curr Hepatol Rep 2015;14:128-38. [PMID: 26328266 DOI: 10.1007/s11901-015-0261-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
220 Singal AG, Nehra M, Adams-Huet B, Yopp AC, Tiro JA, Marrero JA, Lok AS, Lee WM. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol. 2013;108:425-432. [PMID: 23337478 DOI: 10.1038/ajg.2012.449] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
221 Dengler M, Staufer K, Huber H, Stauber R, Bantel H, Weiss KH, Starlinger P, Pock H, Klöters-Plachky P, Gotthardt DN, Rauch P, Lackner C, Stift J, Brostjan C, Gruenberger T, Kumada T, Toyoda H, Tada T, Weiss TS, Trauner M, Mikulits W. Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. Oncotarget 2017;8:46234-48. [PMID: 28526812 DOI: 10.18632/oncotarget.17598] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
222 Oloruntoba OO, Muir AJ. Hepatocellular Carcinoma Risk After Hepatitis C Cure. Curr Treat Options Infect Dis 2018;10:330-6. [DOI: 10.1007/s40506-017-0139-3] [Reference Citation Analysis]
223 Lu Y, Fang Z, Li M, Chen Q, Zeng T, Lu L, Chen Q, Zhang H, Zhou Q, Sun Y, Xue X, Hu Y, Chen L, Su S. Dynamic edge-based biomarker non-invasively predicts hepatocellular carcinoma with hepatitis B virus infection for individual patients based on blood testing. J Mol Cell Biol 2019;11:665-77. [PMID: 30925583 DOI: 10.1093/jmcb/mjz025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
224 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6. [PMID: 23632345 DOI: 10.1097/mcg.0b013e3182872f29] [Cited by in Crossref: 642] [Cited by in F6Publishing: 412] [Article Influence: 71.3] [Reference Citation Analysis]
225 de Sio I, Iadevaia MD, Vitale LM, Niosi M, Del Prete A, de Sio C, Romano L, Funaro A, Meucci R, Federico A, Loguercio C, Romano M. Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single-center retrospective study. United European Gastroenterol J 2014;2:279-87. [PMID: 25083285 DOI: 10.1177/2050640614538964] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
226 Saitta C, Raffa G, Alibrandi A, Brancatelli S, Lombardo D, Tripodi G, Raimondo G, Pollicino T. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) 2017;96:e7266. [PMID: 28658121 DOI: 10.1097/MD.0000000000007266] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
227 González Huezo MS, Sánchez Ávila JF. Consenso mexicano de diagnóstico y manejo del carcinoma hepatocelular. Revista de Gastroenterología de México 2014;79:250-62. [DOI: 10.1016/j.rgmx.2014.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
228 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
229 Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for Hepatocellular Carcinoma in HIV-Infected Patients: Current Evidence and Controversies. Curr HIV/AIDS Rep 2020;17:6-17. [PMID: 31933273 DOI: 10.1007/s11904-019-00475-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
230 Chung JW, Jang ES, Kim J, Jeong SH, Kim N, Lee DH, Lee KH, Kim JW. Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma. Oncotarget 2017;8:106499-510. [PMID: 29290966 DOI: 10.18632/oncotarget.22498] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
231 Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, Nikolaou K. Imaging of HCC-Current State of the Art. Diagnostics (Basel). 2015;5:513-545. [PMID: 26854169 DOI: 10.3390/diagnostics5040513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
232 Natarajan A, Zhang H, Ye W, Huttad L, Tan M, Chua MS, Gambhir SS, So SK. A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts. Cancers (Basel) 2021;13:3977. [PMID: 34439132 DOI: 10.3390/cancers13163977] [Reference Citation Analysis]
233 Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP. Current approaches to the treatment of early hepatocellular carcinoma. Oncologist. 2010;15 Suppl 4:34-41. [PMID: 21115579 DOI: 10.1634/theoncologist.2010-s4-34] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
234 Schwarze V, Marschner C, Völckers W, de Figueiredo GN, Rübenthaler J, Clevert DA. The diagnostic performance of contrast-enhanced ultrasound (CEUS) for evaluating hepatocellular carcinoma (HCC) juxtaposed to MRI findings; a retrospective single-center analysis of 292 patients. Clin Hemorheol Microcirc 2020;76:155-60. [PMID: 32925017 DOI: 10.3233/CH-209213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
235 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
236 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
237 Fateen W, Ryder SD. Screening for hepatocellular carcinoma: patient selection and perspectives. J Hepatocell Carcinoma. 2017;4:71-79. [PMID: 28553624 DOI: 10.2147/jhc.s105777] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
238 Örmeci N. Surveillance of the Patients with High Risk of Hepatocellular Cancer. J Gastrointest Cancer 2017;48:246-9. [PMID: 28634670 DOI: 10.1007/s12029-017-9972-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
239 Tian C, Singal AG. Clinical reminders for hepatocellular carcinoma surveillance: an early step in a long journey. Clin Gastroenterol Hepatol 2015;13:180-2. [PMID: 25086194 DOI: 10.1016/j.cgh.2014.07.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
240 Ramachandran J. Surveillance for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4:S50-S56. [PMID: 25755611 DOI: 10.1016/j.jceh.2014.03.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
241 Singal AG, Tiro J, Li X, Adams-Huet B, Chubak J. Hepatocellular Carcinoma Surveillance Among Patients With Cirrhosis in a Population-based Integrated Health Care Delivery System. J Clin Gastroenterol 2017;51:650-5. [PMID: 27870642 DOI: 10.1097/MCG.0000000000000708] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
242 Grambow E, Weinrich M, Zimpfer A, Kloker K, Klar E. Ectopic Spleen Tissue - an Underestimated Differential Diagnosis of a Hypervascularised Liver Tumour. Viszeralmedizin 2015;31:445-7. [PMID: 26889148 DOI: 10.1159/000442115] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
243 Caviglia GP, Armandi A, Rosso C, Gaia S, Aneli S, Rolle E, Abate ML, Olivero A, Nicolosi A, Guariglia M, Ribaldone DG, Carucci P, Saracco GM, Bugianesi E. Biomarkers of Oncogenesis, Adipose Tissue Dysfunction and Systemic Inflammation for the Detection of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:2305. [PMID: 34064999 DOI: 10.3390/cancers13102305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Lee DH, Lee JM, Chang W, Yoon JH, Kim YJ, Lee JH, Yu SJ, Han JK. Prognostic Role of Liver Stiffness Measurements Using Magnetic Resonance Elastography in Patients with Compensated Chronic Liver Disease. Eur Radiol 2018;28:3513-21. [PMID: 29488082 DOI: 10.1007/s00330-017-5278-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
245 Marquardt JU, Nguyen-Tat M, Galle PR, Wörns MA. Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. Visc Med 2016;32:110-5. [PMID: 27413728 DOI: 10.1159/000445407] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
246 Reichl P, Fang M, Starlinger P, Staufer K, Nenutil R, Muller P, Greplova K, Valik D, Dooley S, Brostjan C. Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Int J Cancer. 2015;137:385-394. [PMID: 25529751 DOI: 10.1002/ijc.29394] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
247 Carbonell G, Taouli B. Abbreviated MR Protocols for Chronic Liver Disease and Liver Cancer. Magn Reson Imaging Clin N Am 2021;29:321-7. [PMID: 34243920 DOI: 10.1016/j.mric.2021.05.003] [Reference Citation Analysis]
248 Weledji EP, Enow Orock G, Ngowe MN, Nsagha DS. How grim is hepatocellular carcinoma? Ann Med Surg (Lond) 2014;3:71-6. [PMID: 25568791 DOI: 10.1016/j.amsu.2014.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
249 Singal AG, El-Serag HB. Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol. 2015;13:2140-2151. [PMID: 26284591 DOI: 10.1016/j.cgh.2015.08.014] [Cited by in Crossref: 269] [Cited by in F6Publishing: 276] [Article Influence: 38.4] [Reference Citation Analysis]
250 Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol 2020;30:4150-63. [PMID: 32166493 DOI: 10.1007/s00330-020-06754-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
251 Offerdahl K, Huber M, Long W, Bottenus N, Nelson R, Trahey G. Occult Regions of Suppressed Coherence in Liver B-Mode Images. Ultrasound Med Biol 2022;48:47-58. [PMID: 34702640 DOI: 10.1016/j.ultrasmedbio.2021.09.007] [Reference Citation Analysis]
252 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
253 Hassett M, Yopp AC, Singal AG, Palmer BF. Surveillance for Hepatocellular Carcinoma: How Can We Do Better? The American Journal of the Medical Sciences 2013;346:308-13. [DOI: 10.1097/maj.0b013e31828318ff] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
254 Sumida Y, Yoneda M, Seko Y, Ishiba H, Hara T, Toyoda H, Yasuda S, Kumada T, Hayashi H, Kobayashi T, Imajo K, Yoneda M, Tada T, Kawaguchi T, Eguchi Y, Oeda S, Takahashi H, Tomita E, Okanoue T, Nakajima A, Japan Study Group Of Nafld Jsg-Nafld. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics (Basel) 2020;10:E579. [PMID: 32785100 DOI: 10.3390/diagnostics10080579] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
255 Mao M, Wang X, Song Y, Sheng H, Han R, Lin W, Dai S. Novel Prognostic Scores Based on Plasma Prothrombin Time and Fibrinogen Levels in Patients With AFP-Negative Hepatocellular Carcinoma. Cancer Control 2020;27:1073274820915520. [PMID: 32216575 DOI: 10.1177/1073274820915520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Kim TH, Yoon JH, Lee JM. Emerging Role of Hepatobiliary Magnetic Resonance Contrast Media and Contrast-Enhanced Ultrasound for Noninvasive Diagnosis of Hepatocellular Carcinoma: Emphasis on Recent Updates in Major Guidelines. Korean J Radiol 2019;20:863-79. [PMID: 31132813 DOI: 10.3348/kjr.2018.0450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
257 Yu R, Xiang X, Tan Z, Zhou Y, Wang H, Deng G. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients. Sci Rep 2016;6:35050. [PMID: 27731353 DOI: 10.1038/srep35050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
258 Purcell Y, Copin P, Paulatto L, Pommier R, Vilgrain V, Ronot M. Hepatocellular carcinoma surveillance: Eastern and Western perspectives. Ultrasonography 2019;38:191-9. [PMID: 30690962 DOI: 10.14366/usg.18043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
259 Mancebo A, Varela M, González-diéguez ML, Navascués CA, Cadahía V, Mesa-álvarez A, Rodrigo L, Rodríguez M. Incidence and risk factors associated with hepatocellular carcinoma surveillance failure: Hepatocellular carcinoma surveillance. Journal of Gastroenterology and Hepatology 2018;33:1524-9. [DOI: 10.1111/jgh.14108] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
260 Yoon JH, Park JW, Lee JM. Noninvasive Diagnosis of Hepatocellular Carcinoma: Elaboration on Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guidelines Compared with Other Guidelines and Remaining Issues. Korean J Radiol 2016;17:7-24. [PMID: 26798212 DOI: 10.3348/kjr.2016.17.1.7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
261 Singh P, Kaur H, Lerner RG, Patel R, Rafiyath SM, Singh Lamba G. Hepatocellular Carcinoma in Non-cirrhotic Liver Without Evidence of Iron Overload in a Patient with Primary Hemochromatosis. Review. J Gastrointest Canc 2012;43:36-9. [DOI: 10.1007/s12029-010-9205-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
262 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
263 Reig M, Forner A, Ávila MA, Ayuso C, Mínguez B, Varela M, Bilbao I, Bilbao JI, Burrel M, Bustamante J, Ferrer J, Gómez MÁ, Llovet JM, De la Mata M, Matilla A, Pardo F, Pastrana MA, Rodríguez-Perálvarez M, Tabernero J, Urbano J, Vera R, Sangro B, Bruix J. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. Med Clin (Barc) 2021;156:463.e1-463.e30. [PMID: 33461840 DOI: 10.1016/j.medcli.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Hou Q, Duan ZJ. Metabonomic window into hepatitis B virus-related hepatic diseases. World J Hepatol 2016; 8(1): 1-8 [PMID: 26783418 DOI: 10.4254/wjh.v8.i1.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
265 Zhen SH, Cheng M, Tao YB, Wang YF, Juengpanich S, Jiang ZY, Jiang YK, Yan YY, Lu W, Lue JM, Qian JH, Wu ZY, Sun JH, Lin H, Cai XJ. Deep Learning for Accurate Diagnosis of Liver Tumor Based on Magnetic Resonance Imaging and Clinical Data. Front Oncol. 2020;10:680. [PMID: 32547939 DOI: 10.3389/fonc.2020.00680] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
266 Marschner CA, Zhang L, Schwarze V, Völckers W, Froelich MF, von Münchhausen N, Schnitzer ML, Geyer T, Fabritius MP, Rübenthaler J, Clevert DA. The diagnostic value of contrast-enhanced ultrasound (CEUS) for assessing hepatocellular carcinoma compared to histopathology; a retrospective single-center analysis of 119 patients1. Clin Hemorheol Microcirc 2020;76:453-8. [PMID: 33216017 DOI: 10.3233/CH-209221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
267 Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review: Review of International HCC Guidelines. Cancer 2014;120:2824-38. [DOI: 10.1002/cncr.28730] [Cited by in Crossref: 153] [Cited by in F6Publishing: 153] [Article Influence: 19.1] [Reference Citation Analysis]
268 Meer SV, Man RA, Siersema PD, Erpecum KJV. Surveillance for hepatocellular carcinoma in chronic liver disease: Evidence and controversies. World J Gastroenterol 2013; 19(40): 6744-6756 [PMID: 24187450 DOI: 10.3748/wjg.v19.i40.6744] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
269 Horowitz JM, Kamel IR, Arif-tiwari H, Asrani SK, Hindman NM, Kaur H, Mcnamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria ® Chronic Liver Disease. Journal of the American College of Radiology 2017;14:S103-17. [DOI: 10.1016/j.jacr.2017.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
270 Weis A, Marquart L, Calvopina DA, Genz B, Ramm GA, Skoien R. Serum MicroRNAs as Biomarkers in Hepatitis C: Preliminary Evidence of a MicroRNA Panel for the Diagnosis of Hepatocellular Carcinoma. Int J Mol Sci. 2019;20. [PMID: 30781550 DOI: 10.3390/ijms20040864] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
271 Tang H, Dong X, Hassan M, Abbruzzese JL, Li D. Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:779-792. [PMID: 21357378 DOI: 10.1158/1055-9965] [Cited by in F6Publishing: 75] [Reference Citation Analysis]
272 Scott RA, Aithal GP, Francis ST, Irving WL. Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diagnosed With Hepatocellular Carcinoma After Initiating Direct-Acting Antiviral Therapy. Gastroenterology 2018;154:1848-50. [DOI: 10.1053/j.gastro.2017.12.047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
273 Lersritwimanmaen P, Nimanong S. Hepatocellular Carcinoma Surveillance: Benefit of Serum Alfa-fetoprotein in Real-world Practice. Euroasian J Hepatogastroenterol 2018;8:83-7. [PMID: 29963472 DOI: 10.5005/jp-journals-10018-1268] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
274 Geh D, Rana FA, Reeves HL. Weighing the benefits of hepatocellular carcinoma surveillance against potential harms. J Hepatocell Carcinoma 2019;6:23-30. [PMID: 30666302 DOI: 10.2147/JHC.S159581] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
275 Lin SH, Lin CY, Hsu NT, Yen YH, Kee KM, Wang JH, Hu TH, Chen CH, Hung CH, Chen CH, Hu JT, Huang YH, Wang TE, Lu SN. Reappraisal of the roles of alpha-fetoprotein in hepatocellular carcinoma surveillance using large-scale nationwide database and hospital-based information. J Formos Med Assoc 2022:S0929-6646(22)00144-9. [PMID: 35450743 DOI: 10.1016/j.jfma.2022.04.001] [Reference Citation Analysis]
276 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
277 Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study. PLoS One 2015;10:e0138907. [PMID: 26398404 DOI: 10.1371/journal.pone.0138907] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
278 An J. [Current Status and Future Directions of Hepatocellular Carcinoma Surveillance Test Based on Cost-effective Analysis]. Korean J Gastroenterol 2021;78:255-60. [PMID: 34824183 DOI: 10.4166/kjg.2021.142] [Reference Citation Analysis]
279 Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54-59. [PMID: 31726817 DOI: 10.3350/cmh.2019.0039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
280 Teufel A, Quante M, Kandulski A, Hirth M, Zhan T, Eckardt M, Thieme R, Kusnik A, Yesmembetov K, Wiest I, Riemann JF, Schlitt HJ, Gockel I, Malfertheiner P, Ebert MP. [Prevention of gastrointestinal cancer]. Z Gastroenterol 2021;59:964-82. [PMID: 34507375 DOI: 10.1055/a-1540-7539] [Reference Citation Analysis]
281 Chang Y, Lee JH. Optimal Modalities for HCC Surveillance in a High-Incidence Region. Clin Liver Dis (Hoboken) 2020;16:236-9. [PMID: 33489094 DOI: 10.1002/cld.923] [Reference Citation Analysis]
282 Brunsing RL, Fowler KJ, Yokoo T, Cunha GM, Sirlin CB, Marks RM. Alternative approach of hepatocellular carcinoma surveillance: abbreviated MRI. Hepatoma Res 2020;6:59. [PMID: 33381651 DOI: 10.20517/2394-5079.2020.50] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
283 Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 2014;5:e45. [PMID: 24384867 DOI: 10.1038/ctg.2013.13] [Cited by in Crossref: 294] [Cited by in F6Publishing: 265] [Article Influence: 36.8] [Reference Citation Analysis]
284 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol 2015; 7(9): 1157-1167 [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 7.0] [Reference Citation Analysis]
285 Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer. 2012;1:94-109. [PMID: 24159577 DOI: 10.1159/000342404] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
286 Worland T, Harrison B, Delmenico L, Dowling D. Hepatocellular Carcinoma Screening Utilising Serum Alpha-Fetoprotein Measurement and Abdominal Ultrasound Is More Effective than Ultrasound Alone in Patients with Non-viral Cirrhosis. J Gastrointest Cancer 2018;49:476-80. [PMID: 28920172 DOI: 10.1007/s12029-017-0006-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
287 Brunsing RL, Chen DH, Schlein A, Wolfson T, Gamst A, Mamidipalli A, Violi NV, Marks RM, Taouli B, Loomba R, Kono Y, Sirlin CB. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience. Radiol Imaging Cancer 2019;1:e190010. [PMID: 33778680 DOI: 10.1148/rycan.2019190010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
288 Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? Curr Hepatol Rep 2017;16:137-45. [PMID: 29085770 DOI: 10.1007/s11901-017-0349-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
289 Piñero F, Tanno M, Aballay Soteras G, Tisi Baña M, Dirchwolf M, Fassio E, Ruf A, Mengarelli S, Borzi S, Fernández N, Ridruejo E, Descalzi V, Anders M, Mazzolini G, Reggiardo V, Marciano S, Perazzo F, Spina JC, McCormack L, Maraschio M, Lagues C, Gadano A, Villamil F, Silva M, Cairo F, Ameigeiras B; Argentinean Association for the Study of Liver Diseases (A.A.E.E.H). Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma. Ann Hepatol 2020;19:546-69. [PMID: 32593747 DOI: 10.1016/j.aohep.2020.06.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
290 Udoh U, Sanabria JD, Rajan PK, Banerjee M, Schade M, Sanabria JA, Smith G, Udoh G, Sodhi K, Pierre S, Shapiro JI, Sanabria JR. Non-Alcoholic Fatty Liver Disease Progression to Non-Alcoholic Steatohepatitis-Related Primary Liver Cancer. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 55-76. [DOI: 10.36255/exonpublications.livercancer.2021.ch3] [Reference Citation Analysis]
291 Panda D. Role of surveillance in prevention of hepatocellular carcinoma. J Clin Exp Hepatol 2014;4:S43-9. [PMID: 25755610 DOI: 10.1016/j.jceh.2014.03.044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
292 Arnone OC, Serranti D, Bartolini E, Mastrangelo G, Stinco M, Trapani S, Ricci S, Resti M, Indolfi G. Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. J Viral Hepat. 2020;27:1344-1351. [PMID: 32853482 DOI: 10.1111/jvh.13382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
293 Al-Naamani K, Al-Hashami Z, Al-Siyabi O, Al-Moundri M, Al-Bahrani B, Al-Sinani S, Al-Zakwani I, Omar H, Al-Busafi SA, Al-Zuhaibi H, AlMamari A, Kamath BR, Al-Kalbani A, Burney IA. Hepatocellular Carcinoma in Oman: An analysis of 284 cases. Sultan Qaboos Univ Med J 2020;20:e316-22. [PMID: 33110647 DOI: 10.18295/squmj.2020.20.03.011] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
294 Han S, Choi JI, Park MY, Choi MH, Rha SE, Lee YJ. The Diagnostic Performance of Liver MRI without Intravenous Contrast for Detecting Hepatocellular Carcinoma: A Case-Controlled Feasibility Study. Korean J Radiol 2018;19:568-77. [PMID: 29962863 DOI: 10.3348/kjr.2018.19.4.568] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
295 Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, Won HJ, Lee SJ, Lee HC, Lee YS. MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. JAMA Oncol. 2017;3:456-463. [PMID: 27657493 DOI: 10.1001/jamaoncol.2016.3147] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 22.6] [Reference Citation Analysis]
296 Taddei TH. A multidisciplinary approach: group dynamics. J Clin Gastroenterol 2013;47 Suppl:S27-9. [PMID: 23632364 DOI: 10.1097/MCG.0b013e31829331de] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
297 Zhang H, Zhu J, Xi L, Xu C, Wu A. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study.World J Surg Oncol. 2019;17:75. [PMID: 31039803 DOI: 10.1186/s12957-019-1619-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
298 Singal AG, Marrero JA, Yopp A. Screening process failures for hepatocellular carcinoma. J Natl Compr Canc Netw 2014;12:375-82. [PMID: 24616543 DOI: 10.6004/jnccn.2014.0039] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
299 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
300 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3517] [Article Influence: 364.2] [Reference Citation Analysis]
301 El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how? Therap Adv Gastroenterol. 2011;4:5-10. [PMID: 21317990 DOI: 10.1177/1756283x10385964] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
302 Rahimi R, Yopp A, Singal A. Current issues and future trends in surveillance for hepatocellular carcinoma. Clin Liver Disease. 2012;1:186-189. [PMID: 31186884 DOI: 10.1002/cld.115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
303 Klingenberg M, Matsuda A, Diederichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67:603-618. [PMID: 28438689 DOI: 10.1016/j.jhep.2017.04.009] [Cited by in Crossref: 178] [Cited by in F6Publishing: 186] [Article Influence: 35.6] [Reference Citation Analysis]
304 Yazici C, Niemeyer DJ, Iannitti DA, Russo MW. Hepatocellular carcinoma and cholangiocarcinoma: an update. Expert Review of Gastroenterology & Hepatology 2013;8:63-82. [DOI: 10.1586/17474124.2014.852468] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
305 Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, Chen WM, Shen CH, Lu CH, Wu CS. Alpha-Fetoprotein Measurement Benefits Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Am J Gastroenterol. 2015;110:836-844; quiz 845. [PMID: 25869392 DOI: 10.1038/ajg.2015.100] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 8.9] [Reference Citation Analysis]
306 Bolondi L, Cillo U, Colombo M, Craxì A, Farinati F, Giannini EG, Golfieri R, Levrero M, Pinna AD, Piscaglia F, Raimondo G, Trevisani F, Bruno R, Caraceni P, Ciancio A, Coco B, Fraquelli M, Rendina M, Squadrito G, Toniutto P. Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. Digestive and Liver Disease 2013;45:712-23. [DOI: 10.1016/j.dld.2013.01.012] [Cited by in Crossref: 103] [Cited by in F6Publishing: 113] [Article Influence: 11.4] [Reference Citation Analysis]
307 Ungtrakul T, Mahidol C, Chun-on P, Laohapand C, Siripongsakun S, Worakitsitisatorn A, Vidhayakorn S, Boonchuay W, Dechma J, Sornsamdang G, Soonklang K, Sriprayoon T, Tanwandee T, Auewarakul CU. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol 2016; 22(34): 7806-7812 [PMID: 27678364 DOI: 10.3748/wjg.v22.i34.7806] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
308 Song P, Tang Q, Feng X, Tang W. Biomarkers: evaluation of clinical utility in surveillance and early diagnosis for hepatocellular carcinoma. Scand J Clin Lab Invest Suppl 2016;245:S70-6. [PMID: 27438343 DOI: 10.1080/00365513.2016.1210328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
309 Santi V, Buccione D, Di Micoli A, Fatti G, Frigerio M, Farinati F, Del Poggio P, Rapaccini G, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Giannini EG, Caturelli E, Chiaramonte M, Bernardi M, Trevisani F. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology 2012;56:397-405. [DOI: 10.1016/j.jhep.2011.05.026] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 7.2] [Reference Citation Analysis]
310 Poté N, Cauchy F, Albuquerque M, Voitot H, Belghiti J, Castera L, Puy H, Bedossa P, Paradis V. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. J Hepatol. 2015;62:848-854. [PMID: 25450201 DOI: 10.1016/j.jhep.2014.11.005] [Cited by in Crossref: 117] [Cited by in F6Publishing: 127] [Article Influence: 14.6] [Reference Citation Analysis]
311 van Aalen EA, Wouters SFA, Verzijl D, Merkx M. Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers. Anal Chem 2022. [PMID: 35438976 DOI: 10.1021/acs.analchem.2c00297] [Reference Citation Analysis]
312 van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KM, Klümpen HJ, Jansen PL, IJzermans JN, van Oijen MG, Siersema PD. Surveillance for hepatocellular carcinoma is associated with increased survival: Results from a large cohort in the Netherlands. J Hepatol. 2015;63:1156-1163. [PMID: 26100498 DOI: 10.1016/j.jhep.2015.06.012] [Cited by in Crossref: 76] [Cited by in F6Publishing: 72] [Article Influence: 10.9] [Reference Citation Analysis]
313 Ali HEA, Abdel Hameed R, Effat H, Ahmed EK, Atef AA, Sharawi SK, Ali M, Abd Elmageed ZY, Abdel Wahab AH. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2017;41:e51-e62. [PMID: 28750770 DOI: 10.1016/j.clinre.2017.06.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
314 Wu X, Meng X, Chang T, Feng S, Lee M, Jaiswal S, Choi EK, Tran L, Jiang H, Wang TD. Multi-modal imaging for uptake of peptide ligand specific for CD44 by hepatocellular carcinoma. Photoacoustics 2022. [DOI: 10.1016/j.pacs.2022.100355] [Reference Citation Analysis]
315 Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-63. [PMID: 30759967 DOI: 10.3350/cmh.2018.0090] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 27.3] [Reference Citation Analysis]
316 Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol 2014;8:71-6. [PMID: 24899827 DOI: 10.4137/CMO.S9926] [Cited by in Crossref: 90] [Cited by in F6Publishing: 54] [Article Influence: 11.3] [Reference Citation Analysis]
317 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
318 Zeng G, Gill US, Kennedy PTF. Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. Gut 2020;69:1907-12. [PMID: 32451325 DOI: 10.1136/gutjnl-2020-321627] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
319 El-Kawy OA, Talaat HM. Preparation, characterization and evaluation of (186) Re-idarubicin: a novel agent for diagnosis and treatment of hepatocellular carcinoma. J Labelled Comp Radiopharm 2016;59:72-7. [PMID: 26725469 DOI: 10.1002/jlcr.3368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
320 Verslype C, Rosmorduc O, Rougier P; ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii41-vii48. [PMID: 22997453 DOI: 10.1093/annonc/mds225] [Cited by in Crossref: 224] [Cited by in F6Publishing: 221] [Article Influence: 24.9] [Reference Citation Analysis]
321 Xin H, Wang K, Hu G, Xie F, Ouyang K, Tang X, Wang M, Wen D, Zhu Y, Qin X. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. PLoS One 2014;9:e85308. [PMID: 24416385 DOI: 10.1371/journal.pone.0085308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
322 Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E; ANRS CO12 CirVir Group. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018;155:1436-1450.e6. [PMID: 30031138 DOI: 10.1053/j.gastro.2018.07.015] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 24.8] [Reference Citation Analysis]
323 Burak KW, Sherman M. Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting. Can J Gastroenterol Hepatol. 2015;29:178-184. [PMID: 25965437 DOI: 10.1155/2015/824263] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
324 Paul SB, Sahu P, Sreenivas V, Nadda N, Gamanagatti SR, Nayak B, Shalimar S, Acharya SK. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy. Scand J Gastroenterol 2019;54:1132-7. [PMID: 31483691 DOI: 10.1080/00365521.2019.1660403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
325 Huang TS, Shyu YC, Turner R, Chen HY, Chen PJ. Diagnostic performance of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, des-gamma carboxyprothrombin, and glypican-3 for the detection of hepatocellular carcinoma: a systematic review and meta-analysis protocol. Syst Rev. 2013;2:37. [PMID: 23738605 DOI: 10.1186/2046-4053-2-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
326 Yang T, Xing H, Wang G, Wang N, Liu M, Yan C, Li H, Wei L, Li S, Fan Z, Shi M, Chen W, Cai S, Pawlik TM, Soh A, Beshiri A, Lau WY, Wu M, Zheng Y, Shen F. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B. Clin Chem. 2019;65:1543-1553. [PMID: 31672853 DOI: 10.1373/clinchem.2019.308965] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
327 Vilar-Gomez E, Chalasani N. Letter: metformin reduces the risk of hepatocellular carcinoma in diabetic patients. Authors' reply. Aliment Pharmacol Ther 2019;50:838-9. [PMID: 31532561 DOI: 10.1111/apt.15486] [Reference Citation Analysis]
328 Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V, Setola S, Fusco R, Petrillo A, Orlando R, Tosone G, Scordino F, Curley SA. Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford) 2013;15:985-90. [PMID: 23607636 DOI: 10.1111/hpb.12080] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
329 Fazeli S, Covarrubias Y, Bassirian S, Cuevas J, Fowler K, Vodkin I, Kono Y, Marks R, Loomba R, Taouli B, Sirlin C, Carlos R. Eliciting Patient Preferences for Hepatocellular Carcinoma Screening: A Choice-Based Conjoint Analysis. Journal of the American College of Radiology 2022. [DOI: 10.1016/j.jacr.2022.01.015] [Reference Citation Analysis]
330 Kim HA, Kim KA, Choi JI, Lee JM, Lee CH, Kang TW, Ku YM, Lee SL, Park YS, Yoon JH, Kim SH, Choi MH. Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol. BMC Cancer 2017;17:877. [PMID: 29268722 DOI: 10.1186/s12885-017-3819-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
331 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 67] [Article Influence: 7.4] [Reference Citation Analysis]
332 Lai Q, Iesari S, Melandro F, Mennini G, Rossi M, Lerut J. The growing impact of alpha-fetoprotein in the field of liver transplantation for hepatocellular cancer: time for a revolution. Transl Gastroenterol Hepatol 2017;2:72. [PMID: 29034345 DOI: 10.21037/tgh.2017.09.05] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
333 Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2014;29:1699-1705. [PMID: 24730702 DOI: 10.1111/jgh.12612] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
334 Lleo A, de Boer YS, Liberal R, Colombo M. The risk of liver cancer in autoimmune liver diseases. Ther Adv Med Oncol 2019;11:1758835919861914. [PMID: 31320937 DOI: 10.1177/1758835919861914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
335 Salgia R, Singal AG. Hepatocellular Carcinoma and Other Liver Lesions. Medical Clinics of North America 2014;98:103-18. [DOI: 10.1016/j.mcna.2013.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
336 Thiesen AL. Hepatocellular Carcinoma in Adults. In: Sergi CM, editor. Liver Cancer. Exon Publications; 2021. pp. 39-54. [DOI: 10.36255/exonpublications.livercancer.2021.ch2] [Reference Citation Analysis]
337 Willatt J, Ruma JA, Azar SF, Dasika NL, Syed F. Imaging of hepatocellular carcinoma and image guided therapies - how we do it. Cancer Imaging 2017;17:9. [PMID: 28259177 DOI: 10.1186/s40644-017-0110-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
338 Ma X, Ding Y, Zeng L. The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma. BMC Cancer 2021;21:418. [PMID: 33858382 DOI: 10.1186/s12885-021-08161-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
339 Canellas R, Rosenkrantz AB, Taouli B, Sala E, Saini S, Pedrosa I, Wang ZJ, Sahani DV. Abbreviated MRI Protocols for the Abdomen. Radiographics 2019;39:744-58. [PMID: 30901285 DOI: 10.1148/rg.2019180123] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
340 Ricco G, Cavallone D, Cosma C, Caviglia GP, Oliveri F, Biasiolo A, Abate ML, Plebani M, Smedile A, Bonino F, Pontisso P, Brunetto MR. Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers.Cancer Biomark. 2018;21:603-612. [PMID: 29278878 DOI: 10.3233/CBM-170551] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
341 Choi SH, Byun JH, Lim YS, Yu E, Lee SJ, Kim SY, Won HJ, Shin YM, Kim PN. Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 2016;64:1099-107. [PMID: 26820629 DOI: 10.1016/j.jhep.2016.01.018] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 9.8] [Reference Citation Analysis]
342 Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders. Clin Liver Dis. 2015;19:309-323. [PMID: 25921665 DOI: 10.1016/j.cld.2015.01.005] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
343 Xu R, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey B, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu J, Hao X, Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nature Mater 2017;16:1155-61. [DOI: 10.1038/nmat4997] [Cited by in Crossref: 282] [Cited by in F6Publishing: 283] [Article Influence: 56.4] [Reference Citation Analysis]
344 Liu Y, Veeraraghavan V, Pinkerton M, Fu J, Douglas MW, George J, Tu T. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Front Microbiol 2021;12:665201. [PMID: 34194408 DOI: 10.3389/fmicb.2021.665201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
345 Bruix J, Sherman M;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. [PMID: 21374666 DOI: 10.1002/hep.24199] [Cited by in Crossref: 5422] [Cited by in F6Publishing: 5185] [Article Influence: 492.9] [Reference Citation Analysis]
346 Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2013;38:703-12. [PMID: 23957569 DOI: 10.1111/apt.12450] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
347 Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. Aliment Pharmacol Ther 2013;38:303-12. [PMID: 23750991 DOI: 10.1111/apt.12370] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
348 Maggs JRL, Suddle AR, Aluvihare V, Heneghan MA. Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2012;35:1113-34. [DOI: 10.1111/j.1365-2036.2012.05072.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
349 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 269] [Article Influence: 27.3] [Reference Citation Analysis]
350 Suk KT, Kim EJ, Kim DJ, Kim HS, Bang CS, Park TY, Baik GH, Kim SE, Park JW, Park SH, Lee MS, Kim HS, Jang MK, Park SH, Choi E, Kim CH, Sung H, Park CK. Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma. J Clin Gastroenterol 2017;51:285-93. [PMID: 27661973 DOI: 10.1097/MCG.0000000000000671] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
351 Komatsu H, Inui A, Yoshio S, Fujisawa T. Pharmacotherapy options for managing hepatitis B in children. Expert Opin Pharmacother 2021;22:449-67. [PMID: 33090882 DOI: 10.1080/14656566.2020.1841165] [Reference Citation Analysis]
352 Conti F, Dall'Agata M, Gramenzi A, Biselli M. Biomarkers for the early diagnosis of bacterial infection and the surveillance of hepatocellular carcinoma in cirrhosis. Biomark Med 2015;9:1343-51. [PMID: 26580585 DOI: 10.2217/bmm.15.100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
353 Lupsor-Platon M, Serban T, Silion AI, Tirpe GR, Tirpe A, Florea M. Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:790. [PMID: 33672827 DOI: 10.3390/cancers13040790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
354 Toy M, Demirci U, So S. Preventing hepatocellular carcinoma: the crucial role of chronic hepatitis B monitoring and antiviral treatment. Hepat Oncol 2014;1:255-7. [PMID: 30190959 DOI: 10.2217/hep.14.10] [Reference Citation Analysis]
355 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1974] [Article Influence: 530.5] [Reference Citation Analysis]
356 Åström E, Stål P, Zenlander R, Edenvik P, Alexandersson C, Haglund M, Rydén I, Påhlsson P. Reverse lectin ELISA for detecting fucosylated forms of α1-acid glycoprotein associated with hepatocellular carcinoma. PLoS One 2017;12:e0173897. [PMID: 28296934 DOI: 10.1371/journal.pone.0173897] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
357 Kim DH, Choi JI. Current status of image-based surveillance in hepatocellular carcinoma. Ultrasonography 2021;40:45-56. [PMID: 33045812 DOI: 10.14366/usg.20067] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
358 Singal AG, Chan V, Getachew Y, Guerrero R, Reisch JS, Cuthbert JA. Predictors of liver transplant eligibility for patients with hepatocellular carcinoma in a safety net hospital. Dig Dis Sci. 2012;57:580-586. [PMID: 21953138 DOI: 10.1007/s10620-011-1904-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
359 Xing H, Yan C, Cheng L, Wang N, Dai S, Yuan J, Lu W, Wang Z, Han J, Zheng Y, Yang T. Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma. Tumor Biol 2016;37:15447-56. [DOI: 10.1007/s13277-016-5443-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
360 Zhu M, Zheng J, Wu F, Kang B, Liang J, Heskia F, Zhang X, Shan Y. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. J Med Virol. 2020;. [PMID: 32043608 DOI: 10.1002/jmv.25704] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
361 Eltabbakh M, Zaghla H, Abdel-Razek W, Elshinnawy H, Ezzat S, Gomaa A, Waked I. Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Med Oncol 2015;32:432. [PMID: 25502085 DOI: 10.1007/s12032-014-0432-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
362 Nam JY, Lee JH, Kim HY, Kim JE, Lee DH, Chang Y, Cho H, Yoo JJ, Lee M, Cho YY, Cho Y, Cho E, Yu SJ, Kim YJ, Yoon JH. Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients. PLoS One 2017;12:e0166188. [PMID: 28099520 DOI: 10.1371/journal.pone.0166188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
363 Tat Trung N, Duong DC, Tong HV, Hien TTT, Hoan PQ, Bang MH, Binh MT, Ky TD, Tung NL, Thinh NT, Sang VV, Thao LTP, Bock CT, Velavan TP, Meyer CG, Song LH, Toan NL. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. PLoS One 2018;13:e0196081. [PMID: 29672637 DOI: 10.1371/journal.pone.0196081] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
364 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet 2018;391:1301-14. [DOI: 10.1016/s0140-6736(18)30010-2] [Cited by in Crossref: 1580] [Cited by in F6Publishing: 1003] [Article Influence: 395.0] [Reference Citation Analysis]
365 Jasirwan COM, Fahira A, Siregar L, Loho I. The alpha-fetoprotein serum is still reliable as a biomarker for the surveillance of hepatocellular carcinoma in Indonesia. BMC Gastroenterol 2020;20:215. [PMID: 32646378 DOI: 10.1186/s12876-020-01365-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
366 Gordon AC, Lewandowski RJ. CBCT-guided TACE-MWA for HCC Measuring up to 5 cm. Acad Radiol 2021:S1076-6332(21)00227-0. [PMID: 34154903 DOI: 10.1016/j.acra.2021.05.012] [Reference Citation Analysis]
367 Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, Lok AS, Marrero JA. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012;21:793-799. [PMID: 22374994 DOI: 10.1158/1055-9965.epi-11-1005] [Cited by in Crossref: 157] [Cited by in F6Publishing: 92] [Article Influence: 15.7] [Reference Citation Analysis]
368 Krishan S, Dhiman RK, Kalra N, Sharma R, Baijal SS, Arora A, Gulati A, Eapan A, Verma A, Keshava S, Mukund A, Deva S, Chaudhary R, Ganesan K, Taneja S, Gorsi U, Gamanagatti S, Madhusudan KS, Puri P, Shalimar, Govil S, Wadhavan M, Saigal S, Kumar A, Thapar S, Duseja A, Saraf N, Khandelwal A, Mukhopadyay S, Gulati A, Shetty N, Verma N. Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System. J Clin Exp Hepatol 2019;9:625-51. [PMID: 31695253 DOI: 10.1016/j.jceh.2019.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
369 Peoc'h K, Manceau H, Karim Z, Wahlin S, Gouya L, Puy H, Deybach JC. Hepatocellular carcinoma in acute hepatic porphyrias: A Damocles Sword. Mol Genet Metab 2019;128:236-41. [PMID: 30413387 DOI: 10.1016/j.ymgme.2018.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
370 Singal AG, Waljee AK, Patel N, Chen EY, Tiro JA, Marrero JA, Yopp AC. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2013;11:1101-8. [PMID: 24029125 DOI: 10.6004/jnccn.2013.0131] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
371 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 52.0] [Reference Citation Analysis]
372 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Reference Citation Analysis]
373 El-Serag HB, Kanwal F. α-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013;11:441-443. [PMID: 23376321 DOI: 10.1016/j.cgh.2012.12.046] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
374 Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Cancer Biomark. 2018;23:235-242. [PMID: 30103302 DOI: 10.3233/cbm-181402] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
375 Mikami S, Tateishi R, Hagiwara S, Sato M, Minami T, Uchino K, Enooku K, Sato T, Nakagawa H, Masuzaki R, Asaoka Y, Kondo Y, Shiina S, Ikeda H, Omata M, Yoshida H, Koike K. Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. Hepatol Res 2015;45:415-22. [PMID: 24861870 DOI: 10.1111/hepr.12365] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
376 Hung YP, Shao YY, Hsu C, Hsu CH, Lee JM, Yang MH, Chao Y. The unique characteristic in peripheral immune cells in patients with advanced hepatocellular carcinoma. J Formos Med Assoc 2021;120:1581-90. [PMID: 33334658 DOI: 10.1016/j.jfma.2020.11.015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
377 Biselli M, Conti F, Gramenzi A, Frigerio M, Cucchetti A, Fatti G, D'Angelo M, Dall'Agata M, Giannini EG, Farinati F, Ciccarese F, Andreone P, Bernardi M, Trevisani F. A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. Br J Cancer 2015;112:69-76. [PMID: 25314061 DOI: 10.1038/bjc.2014.536] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
378 Singal AG, Mukherjee A, Elmunzer BJ, Higgins PD, Lok AS, Zhu J, Marrero JA, Waljee AK. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma. Am J Gastroenterol 2013;108:1723-30. [PMID: 24169273 DOI: 10.1038/ajg.2013.332] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 11.8] [Reference Citation Analysis]
379 Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus α-fetoprotein for hepatocellular carcinoma: A systematic review. Hepatol Res. 2014;44:E11-E25. [PMID: 23834468 DOI: 10.1111/hepr.12201] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
380 Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology 2019;292:390-7. [PMID: 31210614 DOI: 10.1148/radiol.2019190035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
381 Merchante N, Figueruela B, Rodríguez-Fernández M, Rodríguez-Arrondo F, Revollo B, Ibarra S, Galindo MJ, Merino E, Montero M, Téllez F, García-Deltoro M, Rivero-Juárez A, Delgado-Fernández M, Ríos-Villegas MJ, Aguirrebengoa K, García MA, Portu J, Vera-Méndez FJ, Villalobos M, Mínguez C, De Los Santos I, López-Ruz MA, Omar M, Galera C, Macias J, Pineda JA; GEHEP-002 Study Group. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS 2019;33:269-78. [PMID: 30325782 DOI: 10.1097/QAD.0000000000002065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
382 Chagas AL, Mattos AA, Carrilho FJ, Bittencourt PL, Vezozzo DCP, Horvat N, Rocha MS, Alves VAF, Coral GP, Alvares-DA-Silva MR, Barros FMDR, Menezes MR, Monsignore LM, Coelho FF, Silva RFD, Silva RCMA, Boin IFSF, D Albuquerque LAC, Garcia JHP, Felga GEG, Moreira AM, Braghiroli MIFM, Hoff PMG, Mello VB, Dottori MF, Branco TP, Schiavon LL, Costa TFA; Members of the Panel of the 2nd Consensus of the Brazilian Society of Hepatology on the Diagnosis and Management of Hepatocellular Carcinoma. BRAZILIAN SOCIETY OF HEPATOLOGY UPDATED RECOMMENDATIONS FOR DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA. Arq Gastroenterol 2020;57:1-20. [PMID: 32294682 DOI: 10.1590/S0004-2803.202000000-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
383 Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH. Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community. Am J Gastroenterol. 2013;108:416-424. [PMID: 23318478 DOI: 10.1038/ajg.2012.445] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
384 Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, Sirlin CB, Bashir MR. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol 2015;204:527-35. [PMID: 25714281 DOI: 10.2214/AJR.14.12986] [Cited by in Crossref: 62] [Cited by in F6Publishing: 31] [Article Influence: 8.9] [Reference Citation Analysis]
385 Motz VL, White R, Lee R, Vu T, Shin B, McGillen KL. Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center. Abdom Radiol (NY) 2021;46:4170-7. [PMID: 33956204 DOI: 10.1007/s00261-021-03104-w] [Reference Citation Analysis]
386 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
387 Chiang JK, Chih-Wen L, Kao YH. Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. BMJ Open 2017;7:e015936. [PMID: 28645973 DOI: 10.1136/bmjopen-2017-015936] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
388 Kobayashi T, Ichihara K, Goda S, Hidaka I, Yamasaki T, Ishida H. Exploration and time-serial validation of logistic regression models composed of multiple laboratory tests for early detection of HCV-associated hepatocellular carcinoma. Clin Chim Acta 2021;521:137-43. [PMID: 34153275 DOI: 10.1016/j.cca.2021.06.022] [Reference Citation Analysis]
389 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol 2019; 25(13): 1550-1559 [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
390 Carter HE, Jeffrey GP, Ramm GA, Gordon LG. Cost-Effectiveness of a Serum Biomarker Test for Risk-Stratified Liver Ultrasound Screening for Hepatocellular Carcinoma. Value Health 2021;24:1454-62. [PMID: 34593168 DOI: 10.1016/j.jval.2021.04.1286] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Ryu MR, Kang ES, Park HD. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000. J Clin Lab Anal 2019;33:e22921. [PMID: 31131509 DOI: 10.1002/jcla.22921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
392 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 38] [Article Influence: 5.2] [Reference Citation Analysis]
393 Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14. [PMID: 24159567 DOI: 10.1159/000339016] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
394 Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
395 Li T, Li H, Wang A, Su X, Zhao J, Cui Y, Liu J, Hu J. Development And Validation Of A Simple Model For Detection Of Early Hepatocellular Carcinoma In A Liver Cirrhosis Cohort. Cancer Manag Res 2019;11:9379-86. [PMID: 31807067 DOI: 10.2147/CMAR.S221050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, Byun JH, Choi SH, Lee SS, An J, Lim YS. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. J Hepatol 2020;72:718-24. [PMID: 31836549 DOI: 10.1016/j.jhep.2019.12.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 9.3] [Reference Citation Analysis]
397 Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016. Clin Mol Hepatol. 2016;22:7-17. [PMID: 27044761 DOI: 10.3350/cmh.2016.22.1.7] [Cited by in Crossref: 167] [Cited by in F6Publishing: 164] [Article Influence: 27.8] [Reference Citation Analysis]
398 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 201] [Article Influence: 36.3] [Reference Citation Analysis]
399 Jeffrey GP, Gordon L, Ramm G. Hepatocellular carcinoma surveillance in Australia: time to improve the diagnosis of cirrhosis and use liver ultrasound. Medical Journal of Australia 2020;212:297. [DOI: 10.5694/mja2.50521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
400 Gupta M, Gabriel H, Miller FH. Role of Imaging in Surveillance and Diagnosis of Hepatocellular Carcinoma. Gastroenterology Clinics of North America 2018;47:585-602. [DOI: 10.1016/j.gtc.2018.04.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
401 Liao X, Han C, Qin W, Liu X, Yu L, Zhu G, Yu T, Lu S, Su H, Liu Z, Chen Z, Yang C, Huang K, Liu Z, Liang Y, Huang J, Dong J, Li L, Qin X, Ye X, Xiao K, Peng M, Peng T. PLCE1 polymorphisms and expression combined with serum AFP level predicts survival of HBV-related hepatocellular carcinoma patients after hepatectomy. Oncotarget 2017;8:29202-19. [PMID: 28418898 DOI: 10.18632/oncotarget.16346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
402 Ayuso C, Rimola J, Vilana R, Burrel M, Darnell A, García-Criado Á, Bianchi L, Belmonte E, Caparroz C, Barrufet M, Bruix J, Brú C. Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines. Eur J Radiol 2018;101:72-81. [PMID: 29571804 DOI: 10.1016/j.ejrad.2018.01.025] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 20.0] [Reference Citation Analysis]
403 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
404 Park SH, Kim B. Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance. J Liver Cancer 2020;20:25-31. [DOI: 10.17998/jlc.20.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
405 Song JH, Goh MJ, Park Y, Oh JH, Kang W, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal. Scand J Gastroenterol 2021;56:274-80. [PMID: 33399022 DOI: 10.1080/00365521.2020.1866063] [Reference Citation Analysis]
406 Tan CH, Low SC, Thng CH. APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review. Int J Hepatol. 2011;2011:519783. [PMID: 22007313 DOI: 10.4061/2011/519783] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.6] [Reference Citation Analysis]
407 Plentz RR, Boozari B, Malek NP. [Guideline compliant diagnostics of hepatocellular carcinoma]. Radiologe 2014;54:660-3. [PMID: 24981446 DOI: 10.1007/s00117-014-2651-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
408 Li CQ, Huang H, Ruan SM, Hu HT, Xian MF, Xie XY, Lu MD, Kuang M, Wang Y, Chen LD. An assessment of liver lesions using a combination of CEUS LI-RADS and AFP. Abdom Radiol (NY) 2022. [PMID: 35122491 DOI: 10.1007/s00261-022-03428-1] [Reference Citation Analysis]
409 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
410 Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016;25:74-85. [PMID: 27312032 DOI: 10.1016/j.suronc.2016.03.002] [Cited by in Crossref: 165] [Cited by in F6Publishing: 175] [Article Influence: 27.5] [Reference Citation Analysis]
411 Kim MJ. Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver 2011;5:15-21. [PMID: 21461067 DOI: 10.5009/gnl.2011.5.1.15] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
412 Zavadil JA, Herzig MCS, Hildreth K, Foroushani A, Boswell W, Walter R, Reddick R, White H, Zare H, Walter CA. C3HeB/FeJ Mice mimic many aspects of gene expression and pathobiological features of human hepatocellular carcinoma. Mol Carcinog 2019;58:309-20. [PMID: 30365185 DOI: 10.1002/mc.22929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
413 Schütte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis. World J Hepatol 2015; 7(2): 139-149 [PMID: 25729470 DOI: 10.4254/wjh.v7.i2.139] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 6.1] [Reference Citation Analysis]
414 Reichl P, Mikulits W. Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review). Oncol Rep. 2016;36:613-625. [PMID: 27278244 DOI: 10.3892/or.2016.4842] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
415 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
416 Negeri ZF, Beyene J. Statistical methods for detecting outlying and influential studies in meta-analysis of diagnostic test accuracy studies. Stat Methods Med Res 2020;29:1227-42. [PMID: 31203742 DOI: 10.1177/0962280219852747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
417 Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int 2015;35:1862-71. [PMID: 25524812 DOI: 10.1111/liv.12764] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
418 Caviglia GP, Abate ML, Rolle E, Carucci P, Armandi A, Rosso C, Olivero A, Ribaldone DG, Tandoi F, Saracco GM, Ciancio A, Bugianesi E, Gaia S. The Clinical Role of Serum Epidermal Growth Factor Receptor 3 in Hepatitis C Virus-Infected Patients with Early Hepatocellular Carcinoma. Biology (Basel) 2021;10:215. [PMID: 33799723 DOI: 10.3390/biology10030215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Mohamed BF, Serag WM, Abdelal RM, Elsergany HF. S100A14 protein as diagnostic and prognostic marker in hepatocellular carcinoma. Egypt Liver Journal 2019;9. [DOI: 10.1186/s43066-019-0015-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
420 Evangelista J, Zaninotto E, Gaglio A, Ghidini M, Raimondi L. MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma. GastrointestDisord 2021;3:237-46. [DOI: 10.3390/gidisord3040022] [Reference Citation Analysis]